


526 Rec'd PCT/PTO 19 JAN 2001



FORM PTO-1390 (Modified) (REV 5-93)		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				086671/0113	
		U.S. APPLICATION NO. (If known, enter 37 C.F.R. 1.51)		Unassigned 09/744072	
INTERNATIONAL APPLICATION NO. PCT/CA99/00646		INTERNATIONAL FILING DATE July 20, 1999		PRIORITY DATE CLAIMED July 20, 1998	
TITLE OF INVENTION LAFORA'S DISEASE GENE					
APPLICANT(S) FOR DO/EO/US Stephen W. SCHERER, Berge A. MINASSIAN, Antonio DELGADO-ESCUETA, and Guy ROULEAU					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>11. <input checked="" type="checkbox"/> Applicant claims small entity status under 37 CFR 1.27.</p>					
Items 12. to 17. below concern other document(s) or information included:					
<p>12. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>13. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>14. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> Other items or information:</p>					

U.S. APPLIC/ Unassisted 09/744072		INTERNATIONAL APPLICATION NO. PCT/CA99/00646		ATTORNEY'S DOCKET NUMBER 086671/0113	
18. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO \$860.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482)..... \$690.00					
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00					
Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,000.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))					
Claims	Number Filed	Included in Basic Fee	Extra Claims	Rate	
Total Claims	19	20	0	\$18.00	\$0.00
Independent Claims	2	3	0	\$80.00	\$0.00
Multiple dependent claim(s) (if applicable)				\$270.00	
TOTAL OF ABOVE CALCULATIONS =				\$860.00	
Reduction by 1/2 for filing by small entity, if applicable.				\$430.00	
SUBTOTAL =				\$430.00	
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	
TOTAL NATIONAL FEE =				\$430.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	
TOTAL FEES ENCLOSED =				\$430.00	
				Amount to be: refunded \$	
				charged \$	
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$430.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$0.00 to the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u>. A duplicate copy of this sheet is enclosed.</p>					
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>					
<p>SEND ALL CORRESPONDENCE TO:</p> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>Foley & Lardner Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109</p> </div> <div style="width: 50%;"> <p>SIGNATURE </p> <p>NAME BERNHARD D. SAXE</p> <p>REGISTRATION NUMBER 28,665</p> </div> </div>					

09/744072

Attorney Docket No. 86671/113

J002 Rec'd PCT/PTO 19 JAN 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Stephen W. Scherer *et. al.*

Serial No.: Unassigned

Group Art Unit: Unassigned

Filed: January 19, 2001

Examiner: Unassigned

For: LAFORA'S DISEASE GENE

PRELIMINARY AMENDMENT

Commissioner of Patents
Washington, D.C. 20231

Sir:

Prior to examination on the merits of the above-identified application, please amend the application as follows:

IN THE SPECIFICATION

After page 40 of the specification, please insert the following Abstract as page 41, found on the separate sheet below.

IN THE CLAIMS

Claim 7, line 2, after “nucleic acid sequence according to”, delete “any one of claims 1 to 6” and insert – – claim 1 – –

Claim 15, line 1, after “A method”, delete “of according to claim 13 or 14” and insert – – according to claim 7, comprising detecting a deletion of about 25 kb or 75 kb in the sequence of EPM2A shown in SEQ.ID.NO.:1 or Figure 4A, and further – –.

Claim 19, line 2, after “in a protein according to”, delete “any one of claims 17 or 18” and insert – – claim 17 – –.

Add new claims 20-22:

– – 20. An isolated nucleic acid molecule having at least 70% identity to a nucleic acid sequence set forth in SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5.

21. The nucleic acid molecule of claim 20, wherein the nucleic acid molecule has at least 80% identity to a nucleic acid sequence set forth in SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5.

22. An isolated nucleic acid molecule capable of hybridizing to a nucleic acid sequence set forth in SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5, wherein the hybridization first occurs in a solution of 6 x SSC at about 45 °C, followed by a wash in a solution of 2 x SSC at 50 °C.– –

REMARKS

Claims 7, 15, and 19 are amended to remove multiple claim dependencies. New claims 20-22 are supported throughout the specification, such as at page 5, lines 10-23. Claims 1-22 thus are pending for examination on the merits, which is respectfully requested.

Respectfully submitted,



Bernhard D. Saxe

Reg. No. 28,665

January 19, 2001

Date

FOLEY & LARDNER

Suite 500, 3000 K Street, N.W.
Washington, D.C. 20007-5109
(202) 672-5300

-41-

ABSTRACT

Lafora's disease in humans is characterized by the mutation or deletion of an *EPM2A* gene, which encodes a protein, Laforin, having a tyrosine phosphatase domain. Many different sequence mutations, including microdeletions, in *EPM2A* co-segregate with Lafora's disease. Accordingly, detection of mutations in *EPM2A* are useful in diagnosing Lafora's disease. --

094402-00001
T02020-00001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stephen W. SCHERER et al.
Title: LAFORA'S DISEASE GENE
Application No.: 09/744,072
Filing Date: January 19, 2001
Examiner: Unassigned
Art Unit: Unassigned

PRELIMINARY AMENDMENT

Commissioner for Patents
Box CPA
Washington, D.C. 20231

Sir:

Prior to examination on the merits, Applicants respectfully request that the above-identified application be amended as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

On page 2, delete the sixth paragraph after the title "BRIEF DESCRIPTION OF THE DRAWINGS", and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Figure 4A is the nucleotide sequence (SEQ ID NO: 3) and predicted amino acid sequence (SEQ ID NO: 4) of EPM2A (incomplete).

On page 2, delete the seventh paragraph after the title "BRIEF DESCRIPTION OF THE DRAWINGS", and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Figure 4B is an amino acid sequence of the carboxy terminus of transcript A (SEQ ID NO: 25) compared to transcript B (SEQ ID NO: 26).

On page 3, delete the first paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Figure 4C shows the PTP action sites (SEQ ID NOS: 27-32, respectively) of EPMA2A, MTMI (Swiss prot. C13496), PTEN (Swiss prot, O00633, PTP 1B (Swiss prot APT P61F (GenBank L14849) and viral PTP (Swiss prot Af 003534).

On page 11, delete sub-paragraph (a), and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

(a) amplifying the nucleic acid sequences in the sample with primers H1F (5'-GAATGCTCTTTCCACTTTGC-3) (SEQ ID NO: 7) and PTPR (5'-GGCTCCTTAGGGAAATCAG-3') (SEQ ID NO: 8) in a polymerase chain reaction;

On page 12, delete the first sub-paragraph (a), and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

(a) amplifying the nucleic acid sequences in the sample with primers H1F (5'-GAATGCTCTTTCCACTTTGC-3) (SEQ ID NO: 7) and PTPR (5'-GGCTCCTTAGGGAAATCAG-3') (SEQ ID NO: 8) in a polymerase chain reaction;

On page 12, delete the second sub-paragraph (a), and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

(a) amplifying the nucleic acid sequences in the sample with primers JRGXBF (5'-TCCATTGTGCTAATGCTATCTC-3') (SEQ ID NO: 9) and JRGXBR (5'-TCAGCTTGCTTTGAGGATATTT-3') (SEQ ID NO: 10) in a polymerase chain reaction; and

On pages 21-22, delete the last paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Northern blots, cDNA library screening, and RACE. Multiple-tissue (cat. #7760-1) and Human Brain II (cat. #7755-1) Northern blots were purchased from Clontech and hybridization was carried out as recommended by the supplier. The transcript A specific probe was generated using PCR primers 266F (SEQ ID NO: 11) (5'-CGGCACGAGGATTATTCAAG-3') and GSP3 (5'-GCTCGGGTACTGAGGTCTG-3') (SEQ ID NO: 12) which amplified an 190 bp fragment from cDNA clone 266552 (Figure 3). The transcript B specific probe was derived using PCR primers AA490925F (5'-AGTTGTTACACAGGGTTGTTGG-3') (SEQ ID NO: 13) and AA490925R (5'-AGGCTGTACATCAGACAGAAGG-3') (SEQ ID NO: 14) which amplified an 373 bp segment from cDNA SFB14 (Figure 3). We have sequenced the HTF-island shown in Figure 1B at the 5'-end of EPM2A.

On page 22, delete the second full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Mutation Analysis. Mutations were detected by radioactive cycle sequencing using the Thermosequenase Kit (Amersham Life Science) with Qiagen column purified PCR products. The combinations of PCR primer pairs used were JRGXBCF (5'-TCCATTGTGCTAATGCTATCTC-3') (SEQ ID NO: 15) and JRGXBCR (SEQ ID NO: 16) (5'-TCAGCTTGCTTTGAGGATATTT-3'); product size 310 bp, 824F (5'-GCCGAGTACAGATGCTGCC-3' (SEQ ID NO: 17) and 824R (SEQ ID NO: 18) (5'-CACACAGTCCTTTCAGTTCAGG-3'); product size 384 bp, and H1F (5'-GAATGCTCTTTCCTTTGC-3' (SEQ ID NO: 7) and 824R; product size 587 bp. The position of the primers are shown in Figure 3.

On page 25, delete the first full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

The protein encoded by EPM2A contains an amino acid motif (Figure 1C) that corresponds with the consensus sequence (SEQ ID NO: 22), HcxxGxxRS(T), of the catalytic site of PTPs. In addition to the essential cysteine and arginine residues found in all PTPs (Figure 4C), EPM2A contains the expected aspartic acid necessary for

completion of the catalytic reaction, positioned 31-aa N terminal of the cysteine nucleophile.

On page 25, delete the third full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

The deduced amino acid sequence of the newly identified protein(s) indicated that transcripts A, B, C and D encode a 9 amino acid motif (Figure 4A) that corresponds exactly to the consensus sequence (SEQ ID NO: 22), HCxxGxxRS(T), of the active catalytic site of protein tyrosine phosphatases (PTPs) (14,15). So far, no other structural motifs could be identified, and from the sequence it is not apparent if this protein belongs to the receptor-like PTPs, the intracellular PTPs, or the dual specificity phosphatases (DSPs) which dephosphorylate both tyrosine and serine/threonine residues (16). The identification of the EPM2A gene as a putative PTP provides the first clue to understand the basic defect.

On page 25, delete the last full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

At the HTF-island shown in Figure 3, we have identified through GRAIL analysis (<http://compbio.ornl.gov>) an additional putative exon 189 nucleotides in length. An ATG (AUG) triplet is present at the beginning of this predicted ORF and the nucleotide sequence (SEQ ID NO: 23) surrounding the consensus sequence (CCCGCCAUGC) has the proposed features of the consensus sequence (SEQ ID NO: 24) (GCCA/GCCAUGG) of a eukaryotic translation initiation site (12). The predicted start exon maintains open reading frame with the most 5' sequence of transcript A and this combined stretch of 298 nucleotides contains exon/intron junction sequences with splice sites that confirm with the consensus in other mammalian genes. If the predicted exon is part of EPM2A, transcript A would be predicted to be 317 amino acids long.

On page 26, delete the first full paragraph under the title "EPM2A Mutations", and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Using the available genomic structure for the gene, the inventors' screened an affected member from each of 30 Lafora families for mutations by direct DNA sequencing. A total of 14 mutations were detected consisting of 12 different DNA sequence alterations and 2 microdeletions. The mutations are summarized in Table 3. The mutation from C to A at position -12 refers to a mutation that occurs 12 bases upstream from the ATG start codon in Figure 13. Some of the sequence upstream of the ATG is as follows:

(SEQ ID NO: 19) ... gccgggtattcgcgccgCcgccgcccgccATG...

The mutation site at -12 is indicated with a capital C. To date, mutations have been found in 65% of EPM2A families. Some of the mutations are discussed below

On page 26, delete the second full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Two mutations that, based on the current consensus sequences were specific for transcript A, could be detected. Family LD-5 contained a homozygous C to T point mutation which resulted in an arginine to cysteine change affecting a region of unknown function. To test for the presence of the C to T point mutation in family LD-5 in the unaffected population PCR was completed on 54 samples (108 chromosomes) using JRGXBF and JRGXBR primers and the product was blotted in duplicate. One membrane was hybridized with a wild type oligonucleotide (ATCATGACCGTTGCTGTAC) (SEQ ID NO: 20) and the other with LD5 mutant (TCATCATGACTGTTGCTGTAC) (SEQ ID NO: 21) oligonucleotide at 42°C (washing with 5X SSC at room temperature for 20 minutes followed by 2X SSC 20 minutes at 65°C). No mutant alleles were found.

On page 28, delete the first paragraph after the title "**Patients and methods**", and replace this paragraph with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Patients reported here had biopsy-proven Lafora's disease. Polymerase chain reaction (PCR) primer sequences and conditions were:

JRGXBF: (SEQ ID NO: 9) 5'-TCCATTGTGCTAATGCTATCTC-3',

JRGXBR: (SEQ ID NO: 10) 5'-TCAGCTTGCTTTGAGGATATTT-3',

H1F: (SEQ ID NO: 7) 5'-GAATGCTCTTTCCACTTTGC-3,

PTPR: (SEQ ID NO: 8) 5'-GGCTCCTTAGGGAAATCAG-3';

Annealing: 62°; [MgC12] = 1.25mM. Stock DNA was used; PCR products were purified on Qiagen columns. Restriction digests were performed at 37°, and products were run on 3% agarose gels.

IN THE CLAIMS:

In accordance with 37 C.F.R. § 1.121, please substitute for original claims 10, 12 and 15 the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Version With Markings to Show Changes Made."

10. (Amended) A method according to claim 9 wherein the C to T change is detected by a method comprising:

(a) amplifying the nucleic acid sequences in the sample with primers H1F (5'-GAATGCTCTTTCCACTTTGC-3) (SEQ ID NO: 7) and PTPR (5'-GGCTCCTTAGGGAAATCAG-3') (SEQ ID NO: 8) in a polymerase chain reaction;

(b) digesting the amplified sequences with the restriction endonuclease *HaeIII*; and

(c) determining the size of the digested sequences wherein the presence of a fragment of approximately 199bp indicates the sample is from an animal with Lafora's disease or an animal that is a carrier of Lafora's disease.

12. (Amended) A method according to claim 11 wherein the G to A change is detected by a method comprising:

(a) amplifying the nucleic acid sequences in the sample with primers H1F (5'-GAATGCTCTTTCCACTTTGC-3) (SEQ ID NO: 7) and PTPR (5'-GGCTCCTTAGGGAAATCAG-3') (SEQ ID NO: 8) in a polymerase chain reaction;

(b) digesting the amplified sequences with the restriction endonuclease *PstI*; and

(c) determining the size of the digested sequences wherein the presence of at least one fragment of approximately 520bp indicates that the sample is

from an animal that does not have Lafora's disease or an animal that is a carrier of LaFora's disease.

15. (Twice Amended) A method according to claim 7, comprising detecting a deletion of about 25 kb or 75 kb in the sequence of EPM2A shown in SEQ.ID.NO.:1 or Figure 4A, and further comprising:

(a) amplifying the nucleic acid sequences in the sample with primers JRGXBF (5'-TCCATTGTGCTAATGCTATCTC-3') (SEQ ID NO: 9) and JRGXBR (5'-TCAGCTTGCTTTGAGGATATTT-3') (SEQ ID NO: 10) in a polymerase chain reaction; and

(b) detecting amplified sequence wherein the absence of an amplified sequence indicates that the sample is from an animal with Lafora's disease.

REMARKS

Some identifiers were not present in the application as filed. Applicants submit this amendment to specify assignment of SEQ ID NOS 1-32 not present in the application as filed. Applicants respectfully request that the foregoing amendments be made prior to examination of the present application.

Claims 1-22 are pending for examination on the merits, which is respectfully requested.

Respectfully submitted,

Date

July 2, 2001

By

Bernhard D. Saxe

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5427
Facsimile: (202) 672-5399

Bernhard D. Saxe
Attorney for Applicant
Registration No. 28,665

Version With Markings to Show Changes Made

Marked up replacement paragraphs:

Page 2, sixth paragraph after the title "BRIEF DESCRIPTION OF THE DRAWINGS":

Figure 4A is the nucleotide sequence (SEQ ID NO: 3) and predicted amino acid sequence (SEQ ID NO: 4) of EPM2A (incomplete).

Page 2, seventh paragraph after the title "BRIEF DESCRIPTION OF THE DRAWINGS":

Figure 4B is an amino acid sequence of the carboxy terminus of transcript A (SEQ ID NO: 25) compared to transcript B (SEQ ID NO: 26).

Page 3, first paragraph:

Figure 4C shows the PTP action sites (SEQ ID NOS: 27-32, respectively) of EPMA2A, MTMI (Swiss prot. C13496), PTEN (Swiss prot, O00633, PTP 1B (Swiss prot APT P61F (GenBank L14849) and viral PTP (Swiss prot Af 003534).

Page 11, sub-paragraph (a):

(a) amplifying the nucleic acid sequences in the sample with primers H1F (5'-GAATGCTCTTTCCACTTTGC-3') (SEQ ID NO: 7) and PTPR (5'-GGCTCCTTAGGGAAATCAG-3') (SEQ ID NO: 8) in a polymerase chain reaction;

Page 12, first sub-paragraph (a):

(a) amplifying the nucleic acid sequences in the sample with primers H1F (5'-GAATGCTCTTTCCACTTTGC-3') (SEQ ID NO: 7) and PTPR (5'-GGCTCCTTAGGGAAATCAG-3') (SEQ ID NO: 8) in a polymerase chain reaction;

Page 12, second sub-paragraph (a):

(a) amplifying the nucleic acid sequences in the sample with primers JRGXBF (5'-TCCATTGTGCTAATGCTATCTC-3') (SEQ ID NO: 9) and JRGXBR (5'-TCAGCTTGCTTTGAGGATATTT-3') (SEQ ID NO: 10) in a polymerase chain reaction; and

Pages 21-22, last paragraph:

Northern blots, cDNA library screening, and RACE. Multiple-tissue (cat. #7760-1) and Human Brain II (cat. #7755-1) Northern blots were purchased from Clontech and hybridization was carried out as recommended by the supplier. The transcript A specific probe was generated using PCR primers 266F (SEQ ID NO: 11) (5'-CGGCACGAGGATTATTCAAG-3') and GSP3 (5'-GCTCGGGTACTGAGGTCTG-3') (SEQ ID NO: 12) which amplified an 190 bp fragment from cDNA clone 266552 (Figure 3). The transcript B specific probe was derived using PCR primers AA490925F (5'-AGTTGTTACACAGGGTTGTTGG-3') (SEQ ID NO: 13) and AA490925R (5'-AGGCTGTACATCAGACAGAAGG-3') (SEQ ID NO: 14) which amplified an 373 bp segment from cDNA SFB14 (Figure 3). We have sequenced the HTF-island shown in Figure 1B at the 5'-end of EPM2A.

Page 22, second full paragraph:

Mutation Analysis. Mutations were detected by radioactive cycle sequencing using the Thermosequenase Kit (Amersham Life Science) with Qiagen column purified PCR products. The combinations of PCR primer pairs used were JRGXBCF (5'-TCCATTGTGCTAATGCTATCTC-3') (SEQ ID NO: 15) and JRGXBCR (SEQ ID NO: 16) (5'-TCAGCTTGCTTTGAGGATATTT-3'); product size 310 bp, 824F (5'-GCCGAGTACAGATGCTGCC-3' (SEQ ID NO: 17) and 824R (SEQ ID NO: 18) (5'-CACACAGTCCTTTCAGTTCAGG-3'); product size 384 bp, and H1F (5'-GAATGCTCTTCCACTTTGC-3' (SEQ ID NO: 7) and 824R; product size 587 bp. The position of the primers are shown in Figure 3.

Page 25, first full paragraph:

The protein encoded by EPM2A contains an amino acid motif (Figure 1C) that corresponds with the consensus sequence (SEQ ID NO: 22), HcxxGxxRS(T), of the catalytic site of PTPs. In addition to the essential cysteine and arginine residues found in all PTPs (Figure 4C), EPM2A contains the expected aspartic acid necessary for completion of the catalytic reaction, positioned 31-aa N terminal of the cysteine nucleophile.

Page 25, third full paragraph:

The deduced amino acid sequence of the newly identified protein(s) indicated that transcripts A, B, C and D encode a 9 amino acid motif (Figure 4A) that corresponds exactly to the consensus sequence (SEQ ID NO: 22), HCxxGxxRS(T), of the active catalytic site of protein tyrosine phosphatases (PTPs) (14,15). So far, no other structural motifs could be identified, and from the sequence it is not apparent if this protein belongs to the receptor-like PTPs, the intracellular PTPs, or the dual specificity phosphatases (DSPs) which dephosphorylate both tyrosine and serine/threonine residues (16). The identification of the EPM2A gene as a putative PTP provides the first clue to understand the basic defect.

Page 25, last full paragraph:

At the HTF-island shown in Figure 3, we have identified through GRAIL analysis (<http://compbio.ornl.gov>) an additional putative exon 189 nucleotides in length. An ATG (AUG) triplet is present at the beginning of this predicted ORF and the nucleotide sequence (SEQ ID NO: 23) surrounding the consensus sequence (CCCGCCAUGC) has the proposed features of the consensus sequence (SEQ ID NO: 24) (GCCA/GCCAUGG) of a eukaryotic translation initiation site (12). The predicted start exon maintains open reading frame with the most 5' sequence of transcript A and this combined stretch of 298 nucleotides contains exon/intron junction sequences with splice sites that confirm with the consensus in other mammalian genes. If the predicted exon is part of EPM2A, transcript A would be predicted to be 317 amino acids long.

Page 26, first full paragraph under the title "**EPM2A Mutations**":

Using the available genomic structure for the gene, the inventors' screened an affected member from each of 30 Lafora families for mutations by direct DNA sequencing. A total of 14 mutations were detected consisting of 12 different DNA sequence alterations and 2 microdeletions. The mutations are summarized in Table 3. The mutation from C to A at position -12 refers to a mutation that occurs 12 bases upstream from the ATG start codon in Figure 13. Some of the sequence upstream of the ATG is as follows:

(SEQ ID NO: 19) ... gccgggtattcgcgccgCgcgccccgccATG...

The mutation site at -12 is indicated with a capital C. To date, mutations have been found in 65% of EPM2A families. Some of the mutations are discussed below

Page 26, second full paragraph:

Two mutations that, based on the current consensus sequences were specific for transcript A, could be detected. Family LD-5 contained a homozygous C to T point mutation which resulted in an arginine to cysteine change affecting a region of unknown function. To test for the presence of the C to T point mutation in family LD-5 in the unaffected population PCR was completed on 54 samples (108 chromosomes) using JRGXBF and JRGXBR primers and the product was blotted in duplicate. One membrane was hybridized with a wild type oligonucleotide (ATCATGACCGTTGCTGTAC) **(SEQ ID NO: 20)** and the other with LD5 mutant (TCATCATGACTGTTGCTGTAC) **(SEQ ID NO: 21)** oligonucleotide at 42°C (washing with 5X SSC at room temperature for 20 minutes followed by 2X SSC 20 minutes at 65°C). No mutant alleles were found.

Page 28, first paragraph after the title "Patients and methods":

Patients reported here had biopsy-proven Lafora's disease. Polymerase chain reaction (PCR) primer sequences and conditions were:
JRGXBF: **(SEQ ID NO: 9)** 5'-TCCATTGTGCTAATGCTATCTC-3',
JRGXBR: **(SEQ ID NO: 10)** 5'-TCAGCTTGCTTTGAGGATATTT-3',
H1F: **(SEQ ID NO: 7)** 5'-GAATGCTCTTTCCAACCTTGC-3',
PTPR: **(SEQ ID NO: 8)** 5'-GGCTCCTTAGGGAAATCAG-3';
Annealing: 62°; [MgC12] = 1.25mM. Stock DNA was used; PCR products were purified on Qiagen columns. Restriction digests were performed at 37°, and products were run on 3% agarose gels.

Marked up rewritten claims:

10. (Amended) A method according to claim 9 wherein the C to T change is detected by a method comprising:

(a) amplifying the nucleic acid sequences in the sample with primers H1F (5'-GAATGCTCTTTCCAACCTTGC-3') **[(SEQ ID NO: 7)]** and PTPR (5'-GGCTCCTTAGGGAAATCAG-3') **[(SEQ ID NO: 8)]** in a polymerase chain reaction;

(b) digesting the amplified sequences with the restriction endonuclease *HaeIII*; and

(c) determining the size of the digested sequences wherein the presence of a fragment of approximately 199bp indicates the sample is from an animal with Lafora's disease or an animal that is a carrier of Lafora's disease.

12. (Amended) A method according to claim 11 wherein the G to A change is detected by a method comprising:

(a) amplifying the nucleic acid sequences in the sample with primers H1F (5'-GAATGCTCTTTCCACTTTGC-3') [(SEQ ID NO: 7)] and PTPR (5'-GGCTCCTTAGGGAAATCAG-3') [(SEQ ID NO: 8)] in a polymerase chain reaction;

(b) digesting the amplified sequences with the restriction endonuclease *PstI*; and

(c) determining the size of the digested sequences wherein the presence of at least one fragment of approximately 520bp indicates that the sample is from an animal that does not have Lafora's disease or an animal that is a carrier of LaFora's disease.

15. (Twice Amended) A method according to claim 7, comprising detecting a deletion of about 25 kb or 75 kb in the sequence of EPM2A shown in SEQ.ID.NO.:1 or Figure 4A, and further comprising:

(a) amplifying the nucleic acid sequences in the sample with primers JRGXBF (5'-TCCATTGTGCTAATGCTATCTC-3') [(SEQ ID NO: 9)] and JRGXBR (5'-TCAGCTTGCTTTGAGGATATTT-3') [(SEQ ID NO: 10)] in a polymerase chain reaction; and

(b) detecting amplified sequence wherein the absence of an amplified sequence indicates that the sample is from an animal with Lafora's disease.

02 JUL 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 086671/0113

In re patent application of

SCHERER, STEPHEN W. et al.

Serial No. 09/744,072

Filed: July 20, 1999

For: LAFORA'S DISEASE GENE

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and

3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United


09/744,072-070201

Serial No. 09/744,072

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

June 21, 2001
Date


James A. Coburn

HARBOR CONSULTING
Intellectual Property Services
1500A Lafayette Road
Suite 262
Portsmouth, N.H.
800-318-3021

09/744,072 07/02/01

SEQUENCE LISTING

<110> SCHERER, STEPHEN W.
 MINASSIAN, BERGE A.
 ROULEAU, GUY
 DALGADO-ESCUETA, ANTONIO

<120> LAFORA'S DISEASE GENE

<130> 086671/0113

<140> 09/744,072

<141> 1999-07-20

<150> 60/093,495

<151> 1998-07-20

<150> 60/130,269

<151> 1999-04-21

<160> 32

<170> PatentIn Ver. 2.1

<210> 1

<211> 3128

<212> DNA

<213> Homo sapiens

<400> 1

```

atgcgcttcc gctttgggggt ggtggtgcc a cccgccgtgg cggcgcccc gccggagctg 60
ctggtggtgg ggtcgcgccc cgagctgggg cgttgggagc cgcgcggtgc cgtccgcctg 120
aggccggccg gcaccgcggc gggcgacggg gccctggcgc tgcaggagcc gggcctgtgg 180
ctcggggagg tggagctggc ggccgaggag gcggcgcagg acggggcgga gccgggcccgc 240
gtggacacgt tctggtacaa gttcctgaag cgggagccgg gaggagagct ctctgggaa 300
ggcaatggac ctcatcatga ccgttgctgt acttacaatg aaaacaactt ggtggatggt 360
gtgtattgtc tcccaatagg acactggatt gaggccactg ggacacacaa tgaaatgaag 420
cacacaacag acttctatatt taatattgca ggccaccaag ccatgcatta ttcaagaatt 480
ctaccaata tctggctggg tagctgccct cgtcagggtg aacatgttac catcaaactg 540
aagcatgaat tggggattac agctgtaatg aatttccaga ctgaatggga tattgtacag 600
aattcctcag gctgtaaccg ctaccagag cccatgactc cagacactat gattaaacta 660
tatagggaag aaggcttggc ctacatctgg atgccaacac cagatatgag caccgaaggc 720
cgagtacaga tgcctgcccc ggcggtgtgc ctgctgcatg cgctgctgga gaagggacac 780
atcgtgtacg tgcactgcaa cgctgggggt ggccgctcca ccgcggtgtg ctgcggtgtg 840
ctccagtatg tgatgggctg gaatctgagg aaggtgcagt atttcctcat ggccaagagg 900
ccggctgtct acattgacga agaggccttg gcccgggcac aagaagattt tttccagaaa 960
tttggaagg ttcgttcttc tgtgtgtagc ctgtagctgg tcagcctgct tctgccccct 1020
cctgatttcc ctaaggagcc tgggatgatg ttggtcaaat gacctagaaa caaggattct 1080
acctgaactg aaaggactgt gtgacctccc caagccaacc actttcacct gggatgactt 1140
tcgattatgc tttggtttgg ggctgtatgt ttgaaatact ctacaagaaa gctgtggctc 1200
aacacatgag aagaagcacg aagcagttag gctgtacatc agacagaagg gtaatgcgtg 1260
cagttcctgc tgccctgcagg cagacgaggc ctttgcttta cagcactgta tgtgttgac 1320
gatggatccg tgacagcact ttctgtgtgc actgaaactc ttggccatgt agaggaaaaag 1380
atatggagtt atgtggattt catcactagt atgtgtgccg tgagctgggt agttgcaaaa 1440
ggaggaaata aggttagaag cctgaaccgt tacaaaagaa gagctcacta tggcaaaaaa 1500
gtgatggctt tcaggacttg ttttttatcc tgccctcacag ttgttaaagt ctgttccaag 1560
gcatcacctt ctttctctac ccaacaaccc tgtgtaacaa ctaaagtaga attatctctc 1620
atgtgttggt ggtttttcct caaaattacc aaacaaagca aaaaatacc ttgtttttta 1680

```

```

tagttgagat gtcaaggaag ttaaattgag gcttaatgag cataggtagc ttgtccaagg 1740
tctcatgacc agtcaagggc aagctggagt taataatcta tatttatttg actcagcact 1800
gttttcatca caacttgttt tcccagcatc atgtagtgca tttagttttg tctttctcag 1860
ggtatagtca atatgcctgc aggagtttct atagcgagac atagaatagt attctgatca 1920
gttgccaaag aatctaggaa attagttgta ttttgtgcaa gctaatttaa aaacatgatg 1980
ggctgtttta agaccagagt ggaaattcat gagaggaact atactaccaaa aagagcccaa 2040
atgaccaaat ccatggataa ttgcttcaca gccttggcca tcctggctca gctctcaatt 2100
tagtataata tgcagttcct gtgcctccag actatgcagc tcatcaccct aggttctaca 2160
ggaaatacag agatgaacaa ctttgccttc aaaaaatgtg ctgcctagaa aacagacctg 2220
catttcaacc caactgtaat gcaggatttg gaccatgaat gatatgctag aatagaagaa 2280
agagaagtgt ttttttaatt gagagcctct atgtgcaagg tgatatataa tcatatccag 2340
tttaatcttc acaatatcca atgaagaagg tctcattatc tccatgataa agatggggaa 2400
actaaggta gaagggttaa ctcaactgtc tattgtcaca tgatgaataa atagatgaag 2460
tgagatacaa agctgggttt gattcaaagc cttactttc ctaattaaac tatgatgcgt 2520
atatttttt ctgcaccttc ctttcttcca caaacacata ttgatagatg caagagactc 2580
ttatttataa ggcgtggggg acaagaagga tacaaggtaa gtttcagtgg agctcagagg 2640
acggggagat agaactgtgg cacttagggg agatgacatt tgctttgggc agaggcagct 2700
agccaggaca catttccact ataattttac aaagttaaata ttataagcta gcattaagta 2760
aagtgaagtc cagctccctt gctaaaaata actagaggta ataattggta ttcaggtaac 2820
tcatttacag tcataatgtg ttgtgaaaat ttaatcttaa aaattaaatt tttaaactat 2880
gtgggtctgt gaatttcttt aatgtctaag aaatccagct tcataatttc catgatacaa 2940
agatcttttt tcagggtggat ttttaccttt gttccttttg ctctgataga caaaatcagt 3000
ttaggactat taaagaatgt tttggaataa actgtctttt tcctcaatga atgggatgtc 3060
taatgtattt caaaatcacc caaaactttt ggcaaataaa agcattttaa aagaaaaaaa 3120
aaaaaaaaa 3128

```

<210> 2

<211> 331

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Arg Phe Arg Phe Gly Val Val Val Pro Pro Ala Val Ala Gly Ala
  1              5              10              15

Arg Pro Glu Leu Leu Val Val Gly Ser Arg Pro Glu Leu Gly Arg Trp
      20              25              30

Glu Pro Arg Gly Ala Val Arg Leu Arg Pro Ala Gly Thr Ala Ala Gly
      35              40              45

Asp Gly Ala Leu Ala Leu Gln Glu Pro Gly Leu Trp Leu Gly Glu Val
      50              55              60

Glu Leu Ala Ala Glu Glu Ala Ala Gln Asp Gly Ala Glu Pro Gly Arg
      65              70              75              80

Val Asp Thr Phe Trp Tyr Lys Phe Leu Lys Arg Glu Pro Gly Gly Glu
      85              90              95

Leu Ser Trp Glu Gly Asn Gly Pro His His Asp Arg Cys Cys Thr Tyr
      100             105             110

Asn Glu Asn Asn Leu Val Asp Gly Val Tyr Cys Leu Pro Ile Gly His
      115             120             125

```

Trp Ile Glu Ala Thr Gly His Thr Asn Glu Met Lys His Thr Thr Asp
 130 135 140
 Phe Tyr Phe Asn Ile Ala Gly His Gln Ala Met His Tyr Ser Arg Ile
 145 150 155 160
 Leu Pro Asn Ile Trp Leu Gly Ser Cys Pro Arg Gln Val Glu His Val
 165 170 175
 Thr Ile Lys Leu Lys His Glu Leu Gly Ile Thr Ala Val Met Asn Phe
 180 185 190
 Gln Thr Glu Trp Asp Ile Val Gln Asn Ser Ser Gly Cys Asn Arg Tyr
 195 200 205
 Pro Glu Pro Met Thr Pro Asp Thr Met Ile Lys Leu Tyr Arg Glu Glu
 210 215 220
 Gly Leu Ala Tyr Ile Trp Met Pro Thr Pro Asp Met Ser Thr Glu Gly
 225 230 235 240
 Arg Val Gln Met Leu Pro Gln Ala Val Cys Leu Leu His Ala Leu Leu
 245 250 255
 Glu Lys Gly His Ile Val Tyr Val His Cys Asn Ala Gly Val Gly Arg
 260 265 270
 Ser Thr Ala Ala Val Cys Gly Trp Leu Gln Tyr Val Met Gly Trp Asn
 275 280 285
 Leu Arg Lys Val Gln Tyr Phe Leu Met Ala Lys Arg Pro Ala Val Tyr
 290 295 300
 Ile Asp Glu Glu Ala Leu Ala Arg Ala Gln Glu Asp Phe Phe Gln Lys
 305 310 315 320
 Phe Gly Lys Val Arg Ser Ser Val Cys Ser Leu
 325 330

<210> 3

<211> 2940

<212> DNA

<213> Homo sapiens

<400> 3

ggtggagctg gcggccgagg aggcggcgca ggacggggcg gagccggggc gcgtggacac 60
 gttctggtac aagttcctga agcgggagcc gggaggagag ctctcctggg aaggcaatgg 120
 acctcatcat gaccgttgct gtacttacaa tgaaaacaac ttggtggatg gtgtgtattg 180
 tctcccaata ggacactgga ttgaggccac tggacacacc aatgaaatga agcacacaac 240
 agacttctat tttaatatg caggccacca agccatgcat tattcaagaa ttctaccaaa 300
 tatctggctg ggtagctgcc ctcgacaggt ggaacatgtt accatcaaac tgaagcatga 360
 attggggatt acagctgtca tgaatttcca gactgaatgg gatattgttc agaattcctc 420
 atgctgtaac cgctaccag agcccatgac tccagacact atgattaaac tatctaggga 480
 agaaggcttg gcctacatct ggatgccaac accagatatg agcaccgag gccgagtaca 540
 gatgctgccc caggcgggtg gcctgctgca tgcgctgctg gagaaggggac acatcggtga 600
 cgtgcactgc aacgctgggg tgggccgctc caccgcggt gtctgcggct ggctccagta 660
 tgtgatgggc tggaatctga ggaaggtgca gtatttcctc atggccaaga ggccggctgt 720


```

ctacattgac gaagaggcct tggcccgggc acaagaagat tttttccaga aatttgaggaa 780
ggttcgttct tctgtgtgta gcctgtagct ggtcagcctg cttctgcccc ctcctgattt 840
ccctaaggag cctgggatga tgttggtcaa atgacctaga aacaaggatt ctacctgaac 900
tgaaaggact gtgtgacctc cccaagccaa ccactttcac ctgggatgac tttcgattat 960
gcttttggtt ggggctgtat ttttgaaata ctctacaaga aagctgtggc tcaacacatg 1020
agaagaagca cgaagcagtt aggctgtaca tcagacagaa gggtaatgcg tgcagttcct 1080
gctgcctgca ggcagacgag gcctttgctt tacagcactg tatgtgttgc acgatggatc 1140
cgtgacagca ctttcctgtt gcaactgaaac tcttgcccat gtagaggaaa agatatggag 1200
ttatgtggat ttcataccta gtatgtgtgc cgtgagctgg tcagttgcca aaggaggaaa 1260
taagggttaga agcctgaacc gttacaaaag aagagctcac tatggtcaaa aagtgatggc 1320
tttcaggact tgttttttat cctgcctcac agttgttaaa gtctgttcca aggcatacacc 1380
ttccttctct acccaacaac cctgtgtaac aactaaagta gaattatctc tcatttggtg 1440
gtgggttttc ctcaaaatta ccaaacaag caaaaaatac ccttgttttt tatagttgag 1500
atgtcaagga agttaaattg aggcctaatg agcataggta gcttgctcaa ggtctcatga 1560
ccagtcaagg gcaagctgga gttaataatc tatattttatt tgactcagca ctgttttcat 1620
cacaacttgt tttcccgagca tcatgtagtg catttagttt tgtctttctc agggatatagt 1680
caatatgcct gcaggagttt ctatagcgag acatagaata gtattctgat cagttgccaa 1740
agaatctagg aaattagttg tattttgtgc aagctaattt aaaaacatga tgggctgttt 1800
taagaccaga gtggaaattc atgagaggaa ctatactacc aaaagagccc aaatgaccaa 1860
atccatggat aattgcttca cagccttggc catcctggct cagctctcaa tttagtataa 1920
tatgcagttc ctgtgcctcc agactatgca gctcatcacc ctaggttcta caggaaatac 1980
agagatgaac aactttgcct tcaaaaaatg tgctgcctag aaaacagacc tgcatttcaa 2040
cccaactgta atgcaggatt tggaccatga atgatatgct agaatagaag aaagagaagt 2100
gtttttttaa ttgagagcct ctatgtgcaa ggtgatatat aatcatatcc agtttaatct 2160
tcacaatatc caatgaagaa ggtctcatta tctccatgat aaagatgggg aaactaaggt 2220
cagaagggtt aactcaactg tctattgtca catgatgaat aaatagatga agtgagatac 2280
aaagctgggt ttgattcaaa gcccttactt tcctaattaa actatgatgc gtattttatt 2340
ttctgcacct tcttttcttc cacaaacaca tattgataga tgcaagagac tcttatttat 2400
aaggcgtggg ggacaagaag gatacaaggt aagtttcagt ggagctcaga ggacggggag 2460
atagaactgt ggcacttagg ggagatgaca tttgctttgg gcagaggcag ctagccagga 2520
cacatttcca ctataatttt acaaagttaa atttataagc tagcattaag taaagtgaag 2580
tccagctccc ttgctaaaaa taactagagg taataattgg tattcaggta actcatttac 2640
agtcataatg tgttgtgaaa atttaatctt aaaaattaaa tttttaaaact atgtgggtct 2700
gtgaatttct ttaatgtcta agaaatccag cttcataatt tccatgatac aaagatcttt 2760
tttcagggtg atttttacct ttgttccttt tgctctgata gacaaaatca gtttaggact 2820
attaaaagaat gttttggaat aaactgtctt tttcctcaat gaatgggatg tctaattgtat 2880
ttcaaaatca cccaaaactt ttggcaaata aaagcattta aaaagaaaaa aaaaaaaaaa 2940

```

<210> 4
 <211> 268
 <212> PRT
 <213> Homo sapiens

<400> 4
 Val Glu Leu Ala Ala Glu Glu Ala Ala Gln Asp Gly Ala Glu Pro Gly
 1 5 10 15
 Arg Val Asp Thr Phe Trp Tyr Lys Phe Leu Lys Arg Glu Pro Gly Gly
 20 25 30
 Glu Leu Ser Trp Glu Gly Asn Gly Pro His His Asp Arg Cys Cys Thr
 35 40 45
 Tyr Asn Glu Asn Asn Leu Val Asp Gly Val Tyr Cys Leu Pro Ile Gly
 50 55 60

His Trp Ile Glu Ala Thr Gly His Thr Asn Glu Met Lys His Thr Thr
65 70 75 80

Asp Phe Tyr Phe Asn Ile Ala Gly His Gln Ala Met His Tyr Ser Arg
85 90 95

Ile Leu Pro Asn Ile Trp Leu Gly Ser Cys Pro Arg Gln Val Glu His
100 105 110

Val Thr Ile Lys Leu Lys His Glu Leu Gly Ile Thr Ala Val Met Asn
115 120 125

Phe Gln Thr Glu Trp Asp Ile Val Gln Asn Ser Ser Cys Cys Asn Arg
130 135 140

Tyr Pro Glu Pro Met Thr Pro Asp Thr Met Ile Lys Leu Ser Arg Glu
145 150 155 160

Glu Gly Leu Ala Tyr Ile Trp Met Pro Thr Pro Asp Met Ser Thr Ala
165 170 175

Gly Arg Val Gln Met Leu Pro Gln Ala Val Cys Leu Leu His Ala Leu
180 185 190

Leu Glu Lys Gly His Ile Val Tyr Val His Cys Asn Ala Gly Val Gly
195 200 205

Arg Ser Thr Ala Ala Val Cys Gly Trp Leu Gln Tyr Val Met Gly Trp
210 215 220

Asn Leu Arg Lys Val Gln Tyr Phe Leu Met Ala Lys Arg Pro Ala Val
225 230 235 240

Tyr Ile Asp Glu Glu Ala Leu Ala Arg Ala Gln Glu Asp Phe Phe Gln
245 250 255

Lys Phe Gly Lys Val Arg Ser Ser Val Cys Ser Leu
260 265

<210> 5

<211> 915

<212> DNA

<213> Homo sapiens

<400> 5

ccaagaatcg gcacgaggat tattcaagaa ttctacaaa tatctggctg ggtagctgcc 60
ctcgacaggt ggaacatgtt accatcaaac tgaagcatga attggggatt acagctgtca 120
tgaatttcca gactgaatgg gatattgttc agaattcctc atgctgtaac cgctaccag 180
agcccatgac tccagacact atgattaaac tatctagggga agaaggcttg gcctacatct 240
ggatgccaac accagatatg agcacccgag gccgagtaca gatgctgccc caggcgggtgt 300
gcctgctgca tgcgctgctg gagaaggagc acatcgtgta cgtgcactgc aacgctgggg 360
tgggcccgtc caccgcggct gtctgcggct ggctccagta tgtgatgggc tggaatctga 420
ggaagggtgca gtatttcctc atggccaaga ggccggctgt ctacattgac gaagaggcag 480
ctagccagga cacatttcca ctataatttt acaaagttaa atttataagc tagcattaag 540
taaagtgaag tccagctccc ttgctaaaaa taactagagg taataattgg tattcaggta 600
actcatttac agtcataatg tgttgtgaaa atttaattctt aaaaattaaa tttttaaact 660
atgtgggtct gtgaatttct ttaatgtcta agaaatccag cttcataatt tccatgatac 720

09744032 070201

```

aaagatcttt tttcaggtgg atttttacct ttgttccttt tgctctgata gacaaaatca 780
gttttaggact attaaagaat gttttggaat aaactgtctt tttcctcaat gaatgggatg 840
tctaattgat ttcaaaatca cccaaaactt ttggcaaata aaagcattta aaaagaaaaa 900
aaaaaaaaa aaaaaa 915

```

```

<210> 6
<211> 167
<212> PRT
<213> Homo sapiens

```

```

<400> 6
Lys Asn Arg His Glu Asp Tyr Ser Arg Ile Leu Pro Asn Ile Trp Leu
  1              5              10              15

Gly Ser Cys Pro Arg Gln Val Glu His Val Thr Ile Lys Leu Lys His
      20              25              30

Glu Leu Gly Ile Thr Ala Val Met Asn Phe Gln Thr Glu Trp Asp Ile
      35              40              45

Val Gln Asn Ser Ser Cys Cys Asn Arg Tyr Pro Glu Pro Met Thr Pro
      50              55              60

Asp Thr Met Ile Lys Leu Ser Arg Glu Glu Gly Leu Ala Tyr Ile Trp
      65              70              75              80

Met Pro Thr Pro Asp Met Ser Thr Ala Gly Arg Val Gln Met Leu Pro
      85              90              95

Gln Ala Val Cys Leu Leu His Ala Leu Leu Glu Lys Gly His Ile Val
      100             105             110

Tyr Val His Cys Asn Ala Gly Val Gly Arg Ser Thr Ala Ala Val Cys
      115             120             125

Gly Trp Leu Gln Tyr Val Met Gly Trp Asn Leu Arg Lys Val Gln Tyr
      130             135             140

Phe Leu Met Ala Lys Arg Pro Ala Val Tyr Ile Asp Glu Glu Ala Ala
      145             150             155             160

Ser Gln Asp Thr Phe Pro Leu
      165

```

```

<210> 7
<211> 20
<212> DNA
<213> Homo sapiens

```

```

<400> 7
gaatgctctt tccactttgc

```

20

```

<210> 8
<211> 19
<212> DNA

```

T02020"204460

19

22

22

20

19

22

22

<210> 15
 <211> 22
 <212> DNA
 <213> Homo sapiens

<400> 15
 tccattgtgc taatgctatc tc 22

<210> 16
 <211> 22
 <212> DNA
 <213> Homo sapiens

<400> 16
 tcagcttgct ttgaggatat tt 22

<210> 17
 <211> 19
 <212> DNA
 <213> Homo sapiens

<400> 17
 gccgagtaca gatgctgcc 19

<210> 18
 <211> 22
 <212> DNA
 <213> Homo sapiens

<400> 18
 cacacagtcc tttcagttca gg 22

<210> 19
 <211> 33
 <212> DNA
 <213> Homo sapiens

<400> 19
 gcccggtat tcgcgccgcc gccgccgcc atg 33

<210> 20
 <211> 19
 <212> DNA
 <213> Homo sapiens

<400> 20
 atcatgaccg ttgctgtac 19

<210> 21
 <211> 21

094403-070001

21

<400> 24
gccrccaugg 10

<210> 25
 <211> 22
 <212> PRT
 <213> Homo sapiens

<400> 25
 Leu Ala Arg Ala Gln Glu Asp Phe Phe Gln Lys Phe Gly Lys Val Arg
 1 5 10 15
 Ser Ser Val Cys Ser Leu
 20

<210> 26
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 26
 Ala Ser Gln Asp Thr Phe Pro Leu
 1 5

<210> 27
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 27
 Val His Cys Asn Ala Gly Val Gly Arg Ser Thr
 1 5 10

<210> 28
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 28
 Val His Cys Ser Asp Gly Trp Asp Arg Thr Ala
 1 5 10

<210> 29
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 29
 Ile His Cys Lys Ala Gly Lys Gly Arg Thr Gly
 1 5 10

<210> 30
 <211> 11
 <212> PRT
 <213> Homo sapiens

10304024450

<400> 30
Val His Cys Ser Ala Gly Ile Gly Arg Ser Gly
1 5 10

<210> 31
<211> 11
<212> PRT
<213> Homo sapiens

<400> 31
Val His Cys Ser Ala Gly Ile Gly Arg Ser Gly
1 5 10

<210> 32
<211> 11
<212> PRT
<213> Homo sapiens

<400> 32
Val His Cys Gln Ala Gly Ile Ser Arg Ser Ala
1 5 10

094407-020460

Title: Lafora's Disease Gene

FIELD OF THE INVENTION

The invention relates to a novel gene, EPM2A, that is involved in Lafora's disease; the protein, Laforin, encoded by the gene; and methods of diagnosing and treating Lafora's disease.

BACKGROUND OF THE INVENTION

The epilepsies constitute one of the most common neurological disorders affecting 40 million people worldwide (1). Within the spectrum of epileptic syndromes is a group of heterogeneous inherited disorders named the Progressive Myoclonus Epilepsies (PME) in which progressive neurological decline and worsening primarily myoclonic seizures follow an initial period of normal development (2,3,4). Lafora's disease (LD) is an autosomal recessive and genetically heterogeneous form of Progressive Myoclonus Epilepsy characterized by polyglucosan inclusions seizures and cumulative neurological deterioration. The onset occurs during late childhood and usually results in death within a decade of first symptoms. With few exceptions, patients with LD follow a homogeneous clinical course (4) despite the existence of genetic locus heterogeneity (5). Biopsy (or autopsy) of various tissues including brain, liver, muscle, and skin reveals characteristic periodic acid-Schiff positive polyglucosan inclusions (Lafora bodies) (6-9). Substantial biochemical and histological studies of these bodies suggest LD is a generalized storage disease (8,10,11), but the presumed enzymatic defect remains unknown.

Linkage analysis and homozygosity mapping initially localized a Lafora's disease locus (EPM2A) to a region at chromosome 6q23-q25 bounded by the genetic markers D6S1003 and D6S311 (12,13). However, there is a need in the art to more clearly define the region(s) mutated in Lafora's disease to allow for the development of accurate diagnostic assays for Lafora's disease. More specifically, there is a need to sequence the gene associated with Lafora's Disease and to identify mutations and/or deletions in the gene that are causative of Lafora's Disease.

SUMMARY OF THE INVENTION

The present inventors have identified a novel gene, EPM2A, that is deleted or mutated in people with Lafora's disease. Using a positional cloning approach the inventors have identified at chromosome 6q24 the EPM2A gene that encodes a protein with consensus amino acid sequence indicative of a tyrosine phosphatase. Accordingly, the present invention provides an isolated nucleic acid molecule containing a sequence encoding an active catalytic site of a protein tyrosine phosphatase which is associated with Lafora's disease.

In one embodiment of the invention, an isolated nucleic acid molecule is provided having a sequence as shown in SEQ.ID.NO.:1 or Figure 13.

Preferably, the purified and isolated nucleic acid molecule comprises:

(a) a nucleic acid sequence as shown in SEQ.ID.NO.:1 and Figure 13, wherein T can also be U;

(b) nucleic acid sequences complementary to (a);

5 (c) nucleic acid sequences which are homologous to (a) or (b);

(d) a fragment of (a) to (c) that is at least 15 bases, preferably 20 to 30 bases, and which will hybridize to (a) to (d) under stringent hybridization conditions; or

(e) a nucleic acid molecule differing from any of the nucleic acids of (a) to (c) in codon sequences due to the degeneracy of the genetic code.

10 Fourteen different mutations in EPM2A in 24 families have been found that co-segregate with Lafora's disease. These alterations would be predicted to abolish or cause deleterious effects on the protein product, Laforin, resulting in the primary defect in a large portion of patients with the disease. Accordingly, the present invention provides a method of detecting Lafora's disease comprising detecting a mutation or deletion in the EPM2A gene
15 in a sample from a mammal. A mutation can be detected by sequencing the EPM2A gene, in particular in the region in the gene between markers D6S1003 and D6S1042, in a patient and comparing the sequence to the wild type EPM2A sequence shown in Figure 13 to determine if a mutation or deletion is present. A mutation or deletion can also be detected by assaying for the protein product encoded by EPM2A, Laforin.

20 Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described in relation to the drawings in which:

Figure 1 is a physical map of the Lafora's disease critical region.

Figure 2A shows a refined mapping of the Lafora disease gene for Lafora family
30 LD39.

Figure 2B is for Lafora family LD-L4.

Figure 3 shows overlapping cDNA clones aligned with genomic DNA segments.

Figure 4A is the nucleotide sequence and predicted amino acid sequence of EPM2A (incomplete).

35 Figure 4B is an amino acid sequence of the carboxy terminus of transcript A compared to transcript B.

Figure 4C shows the PTP action sites of EPM2A, MTMI (Swiss prot. C13496), PTEN (Swiss prot, O00633, PTP 1B (Swiss prot APT P61F (GenBank LI4849) and viral PTP (Swiss prot Af 003534).

Figure 5 is a Northern blot showing RNA expression pattern of EPM2A.

5 Figure 6A shows representative mutations found in Lafora's family LD-16.

Figure 6B shows Lafora's family LD-33.

Figure 7 is a nucleotide sequence of transcript A cDNA of the EPM2A gene (SEQ.ID.NO.:3).

Figure 8 is the predicted amino acid sequence of transcript A (SEQ.ID.NO.:4).

10 Figure 9 is a nucleotide sequence of transcript B cDNA of the EPM2A gene (SEQ.ID.NO.: 5).

Figure 10 is the predicted amino acid sequence of transcript B (SEQ.ID.NO.: 6).

Figure 11 is a refined map of the deletion breakpoints in families LD-L4, LD9 and LD1.

15 Figure 12A is a restriction map of PCR products with primers H1F/PTPR.

Figure 12B is the *HaeIII* and *PstI* digestion of the H1F/PTPR PCR product.

Figure 13 is the complete nucleic acid sequence of EPM2A. This is also shown in SEQ.ID.NO.:1.

20 Figure 14 is the complete amino acid sequence of EPM2A. This is also shown in SEQ.ID.NO.:2.

DETAILED DESCRIPTION OF THE INVENTION

The present inventors constructed a high resolution physical map across the EPM2A gene to provide additional genetic and physical mapping reagents for refined localization of the disease gene. It was determined that the previously established
25 critical region encompassed approximately 1.2 Mb of DNA. The map allowed the positioning of the location of 7 genetic markers, the metabotropic glutamate receptor 1 (GRM1) gene, and 6 expressed sequence tags (EST) clusters (tentatively named LDCR1-LDCR6), within the interval (Figure 1). The genetic markers were then used to test for regions of homozygosity in each of the 30 families with Lafora's disease that appeared
30 genotypically to arise due to mutations in a gene at 6q23-q25. In a single family (LD39), an extended chain of homozygous markers within the previously established critical region allowed the inventors to, tentatively, redefine the telomeric boundary at D6S1042 (Figure 2A). Simultaneously, a homozygous deletion of marker D6S1703 in the affected of a consanguineous family (LD-L4) (Figure 2B) was detected. This observation confirmed the
35 newly defined critical region to that 600 kb of DNA between D6S1003 and D6S1042, but more importantly, pinpointed the site of the disease gene within this region.

I. NUCLEIC ACID MOLECULES OF THE INVENTION

As hereinbefore mentioned, the present invention relates to isolated nucleic acid molecules that are involved in Lafora's disease. The term "isolated" refers to a nucleic acid substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors, or other chemicals when chemically synthesized. The term "nucleic acid" is intended to include DNA and RNA and can be either double stranded or single stranded.

Broadly stated, the present invention provides an isolated nucleic acid molecule containing a sequence encoding an active catalytic site of a protein tyrosine phosphatase which is associated with Lafora's disease. The isolated nucleic acid molecule is preferably the EPM2A gene associated with Lafora's disease. In an embodiment of the invention, the isolated nucleic acid molecule has a sequence as shown in SEQ.ID.NO.:1 and Figure 13.

Preferably, the purified and isolated nucleic acid molecule comprises

- (a) a nucleic acid sequence as shown in SEQ.ID.NO.:1 and Figure 13, wherein T can also be U;
- (b) nucleic acid sequences complementary to (a);
- (c) nucleic acid sequences which are homologous to (a) or (b);
- (d) a fragment of (a) to (c) that is at least 15 bases, preferably 20 to 30 bases, and which will hybridize to (a) to (d) under stringent hybridization conditions; or
- (e) a nucleic acid molecule differing from any of the nucleic acids of (a) to (c) in codon sequences due to the degeneracy of the genetic code.

The inventors have also isolated alternate forms of EPM2A which are generally referred to as transcript A and transcript B, herein. The nucleic acid sequence of transcript A is shown in SEQ.ID.NO.:3 and Figure 7. The nucleic acid sequence of transcript B is shown in SEQ.ID.NO.:5 and Figure 9. The amino acid sequence encoded by transcript A is shown in SEQ.ID.NO.:4 and Figure 8. The amino acid sequence encoded by transcript B is shown in SEQ.ID.NO.:6 and Figure 10.

The nucleic acid sequences shown in SEQ.ID.NOS.: 1, 3 and 5 (or Figures 13, 7 and 9, respectively) can be collectively referred to herein as "the nucleic acid molecules of the invention". The amino acid sequences shown in SEQ.ID.NOS.: 2, 4 and 6 (or Figures 4A, 8 and 10, respectively) may be collectively referred to herein as the "proteins of the invention".

It will be appreciated that the invention includes nucleic acid molecules encoding truncations of the proteins of the invention, and analogs and homologs of the proteins of the invention and truncations thereof, as described below. It will further be appreciated that variant forms of the nucleic acid molecules of the invention which arise

by alternative splicing of an mRNA corresponding to a cDNA of the invention are encompassed by the invention.

Further, it will be appreciated that the invention includes nucleic acid molecules comprising nucleic acid sequences having substantial sequence homology with the
5 nucleic acid sequences of the invention and fragments thereof. The term "sequences having substantial sequence homology" means those nucleic acid sequences which have slight or inconsequential sequence variations from these sequences, i.e. the sequences function in substantially the same manner to produce functionally equivalent proteins. The variations may be attributable to local mutations or structural modifications.

10 Generally, nucleic acid sequences having substantial homology include nucleic acid sequences having at least 70%, preferably 80-90% identity with the nucleic acid sequences of the invention.

Another aspect of the invention provides a nucleic acid molecule, and fragments thereof having at least 15 bases, which hybridizes to the nucleic acid molecules of the
15 invention under hybridization conditions, preferably stringent hybridization conditions. Appropriate stringency conditions which promote DNA hybridization are known to those skilled in the art, or may be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, the following may be employed: 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C. The
20 stringency may be selected based on the conditions used in the wash step. For example, the salt concentration in the wash step can be selected from a high stringency of about 0.2 x SSC at 50°C. In addition, the temperature in the wash step can be at high stringency conditions, at about 65°C.

Isolated and purified nucleic acid molecules having sequences which differ from
25 the nucleic acid sequence shown in SEQ.ID.NO.:1 or SEQ.ID.NO.:3 or SEQ.ID.NO.:5 due to degeneracy in the genetic code are also within the scope of the invention.

Nucleic acid molecules from the EPM2A gene can be isolated by preparing a labelled nucleic acid probe based on all or part of the nucleic acid sequences as shown in SEQ.ID.NO.:1 and Figure 13, and using this labelled nucleic acid probe to screen an
30 appropriate DNA library (e.g. a cDNA or genomic DNA library). Nucleic acids isolated by screening of a cDNA or genomic DNA library can be sequenced by standard techniques.

Nucleic acid molecules of the invention can also be isolated by selectively amplifying a nucleic acid using the polymerase chain reaction (PCR) methods and cDNA or genomic DNA. It is possible to design synthetic oligonucleotide primers from the nucleic
35 acid molecules as shown in SEQ.ID.NO.:1 and Figure 13, for use in PCR. A nucleic acid can be amplified from cDNA or genomic DNA using these oligonucleotide primers and standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. It will be appreciated

that cDNA may be prepared from mRNA, by isolating total cellular mRNA by a variety of techniques, for example, by using the guanidinium-thiocyanate extraction procedure of Chirgwin et al., Biochemistry, 18, 5294-5299 (1979). cDNA is then synthesized from the mRNA using reverse transcriptase (for example, Moloney MLV reverse transcriptase
5 available from Gibco/BRL, Bethesda, MD, or AMV reverse transcriptase available from Seikagaku America, Inc., St. Petersburg, FL).

An isolated nucleic acid molecule of the invention which is RNA can be isolated by cloning a cDNA encoding a novel protein of the invention into an appropriate vector which allows for transcription of the cDNA to produce an RNA molecule which encodes the
10 Laforin protein. For example, a cDNA can be cloned downstream of a bacteriophage promoter, (e.g. a T7 promoter) in a vector, cDNA can be transcribed *in vitro* with T7 polymerase, and the resultant RNA can be isolated by standard techniques.

A nucleic acid molecule of the invention may also be chemically synthesized using standard techniques. Various methods of chemically synthesizing
15 polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See e.g., Itakura et al. U.S. Patent No. 4,598,049; Caruthers et al. U.S. Patent No. 4,458,066; and Itakura U.S. Patent Nos. 4,401,796 and 4,373,071).

The initiation codon and untranslated sequences of the nucleic acid molecules of
20 the invention may be determined using currently available computer software designed for the purpose, such as PC/Gene (IntelliGenetics Inc., Calif.). Regulatory elements can be identified using conventional techniques. The function of the elements can be confirmed by using these elements to express a reporter gene which is operatively linked to the elements. These constructs may be introduced into cultured cells using standard procedures. In addition
25 to identifying regulatory elements in DNA, such constructs may also be used to identify proteins interacting with the elements, using techniques known in the art.

The sequence of a nucleic acid molecule of the invention may be inverted relative to its normal presentation for transcription to produce an antisense nucleic acid molecule. Preferably, an antisense sequence is constructed by inverting a region preceding
30 the initiation codon or an unconserved region. In particular, the nucleic acid sequences contained in the nucleic acid molecules of the invention or a fragment thereof, preferably a nucleic acid sequence shown in SEQ.ID.NO.:1, SEQ.ID.NO.:3 or SEQ.ID.NO.:5 may be inverted relative to its normal presentation for transcription to produce antisense nucleic acid molecules.

35 The antisense nucleic acid molecules of the invention or a fragment thereof, may be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed with mRNA or the native gene e.g.

phosphorothioate derivatives and acridine substituted nucleotides. The antisense sequences may be produced biologically using an expression vector introduced into cells in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense sequences are produced under the control of a high efficiency regulatory region, the activity of which may be determined by the cell type into which the vector is introduced.

The invention also provides nucleic acids encoding fusion proteins comprising a novel protein of the invention and a selected protein, or a selectable marker protein (see below).

II. NOVEL PROTEINS OF THE INVENTION

The invention further includes an isolated protein encoded by the nucleic acid molecules of the invention. Within the context of the present invention, a protein of the invention may include various structural forms of the primary protein which retain biological activity.

Broadly stated, the present invention provides an isolated protein containing a tyrosine phosphatase domain and which is associated with Lafora's disease.

In a preferred embodiment of the invention, the protein has the amino acid sequence as shown in SEQ ID NO:2 and Figure 14. In another embodiment, the protein has the amino acid sequence shown in SEQ.ID.NO.:4 (or Figure 8) or SEQ.ID.NO.: 6 (or Figure 10).

In addition to full length amino acid sequences the proteins of the present invention also include truncations of the protein, and analogs, and homologs of the protein and truncations thereof as described herein. Truncated proteins may comprise peptides of at least fifteen amino acid residues.

Analog of the protein having the amino acid sequence shown in SEQ.ID.NO.:2 (Figure 14) or SEQ.ID.NO.:4 (Figure 8) or SEQ.ID.NO.:6 (Figure 10) and/or truncations thereof as described herein, may include, but are not limited to an amino acid sequence containing one or more amino acid substitutions, insertions, and/or deletions. Amino acid substitutions may be of a conserved or non-conserved nature. Conserved amino acid substitutions involve replacing one or more amino acids of the proteins of the invention with amino acids of similar charge, size, and/or hydrophobicity characteristics. When only conserved substitutions are made the resulting analog should be functionally equivalent. Non-conserved substitutions involve replacing one or more amino acids of the amino acid sequence with one or more amino acids which possess dissimilar charge, size, and/or hydrophobicity characteristics.

One or more amino acid insertions may be introduced into the amino acid sequences shown in SEQ.ID.NO.:2 (Figure 14) or SEQ.ID.NO.:4 (Figure 8) or SEQ.ID.NO.:6 (Figure 10). Amino acid insertions may consist of single amino acid residues or sequential amino acids ranging from 2 to 15 amino acids in length. For example, amino acid insertions

may be used to destroy target sequences so that the protein is no longer active. This procedure may be used *in vivo* to inhibit the activity of a protein of the invention.

Deletions may consist of the removal of one or more amino acids, or discrete portions from the amino acid sequence shown in SEQ.ID.NO.:2 (Figure 14) or SEQ.ID.NO.:4 (Figure 8) or SEQ.ID.NO.:6 (Figure 10). The deleted amino acids may or may not be contiguous. The lower limit length of the resulting analog with a deletion mutation is about 10 amino acids, preferably 100 amino acids.

Analogues of a protein of the invention may be prepared by introducing mutations in the nucleotide sequence encoding the protein. Mutations in nucleotide sequences constructed for expression of analogs of a protein of the invention must preserve the reading frame of the coding sequences. Furthermore, the mutations will preferably not create complementary regions that could hybridize to produce secondary mRNA structures, such as loops or hairpins, which could adversely affect translation of the receptor mRNA.

Mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed site specific mutagenesis procedures may be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Deletion or truncation of a protein of the invention may also be constructed by utilizing convenient restriction endonuclease sites adjacent to the desired deletion. Subsequent to restriction, overhangs may be filled in, and the DNA religated. Exemplary methods of making the alterations set forth above are disclosed by Sambrook et al (Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, 1989).

The proteins of the invention also include homologs of the amino acid sequence shown in SEQ.ID.NO.:2 (Figure 14) or SEQ.ID.NO.:4 (Figure 8) or SEQ.ID.NO.:6 (Figure 10) and/or truncations thereof as described herein. Such homologs are proteins whose amino acid sequences are comprised of amino acid sequences that hybridize under stringent hybridization conditions (see discussion of stringent hybridization conditions herein) with a probe used to obtain a protein of the invention. Preferably, homologs of a protein of the invention will have a tyrosine phosphatase region which is characteristic of the protein.

A homologous protein includes a protein with an amino acid sequence having at least 70%, preferably 80-90% identity with the amino acid sequence as shown in SEQ.ID.NO.:2 (Figure 14) or SEQ.ID.NO.:4 (Figure 8) or SEQ.ID.NO.:6 (Figure 10).

The invention also contemplates isoforms of the proteins of the invention. An isoform contains the same number and kinds of amino acids as a protein of the invention, but the isoform has a different molecular structure. The isoforms contemplated by the present

invention are those having the same properties as a protein of the invention as described herein.

The present invention also includes a protein of the invention conjugated with a selected protein, or a selectable marker protein (see below) to produce fusion proteins.

- 5 Additionally, immunogenic portions of a protein of the invention are within the scope of the invention.

The proteins of the invention (including truncations, analogs, etc.) may be prepared using recombinant DNA methods. Accordingly, the nucleic acid molecules of the present invention having a sequence which encodes a protein of the invention may be
10 incorporated in a known manner into an appropriate expression vector which ensures good expression of the protein. Possible expression vectors include but are not limited to cosmids, plasmids, or modified viruses (e.g. replication defective retroviruses, adenoviruses and adeno-associated viruses), so long as the vector is compatible with the host cell used. The expression vectors are "suitable for transformation of a host cell", means that the
15 expression vectors contain a nucleic acid molecule of the invention and regulatory sequences selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid molecule. Operatively linked is intended to mean that the nucleic acid is linked to regulatory sequences in a manner which allows expression of the nucleic acid.

The invention therefore contemplates a recombinant expression vector of the
20 invention containing a nucleic acid molecule of the invention, or a fragment thereof, and the necessary regulatory sequences for the transcription and translation of the inserted protein-sequence. Suitable regulatory sequences may be derived from a variety of sources, including bacterial, fungal, or viral genes (For example, see the regulatory sequences described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic
25 Press, San Diego, CA (1990). Selection of appropriate regulatory sequences is dependent on the host cell chosen, and may be readily accomplished by one of ordinary skill in the art. Examples of such regulatory sequences include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a ribosomal binding sequence, including a translation initiation signal. Additionally, depending on the host cell chosen and the vector
30 employed, other sequences, such as an origin of replication, additional DNA restriction sites, enhancers, and sequences conferring inducibility of transcription may be incorporated into the expression vector. It will also be appreciated that the necessary regulatory sequences may be supplied by the native protein and/or its flanking regions.

The invention further provides a recombinant expression vector comprising a
35 DNA nucleic acid molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression, by transcription of the DNA molecule, of an RNA molecule which is antisense to a nucleotide sequence comprising the nucleotides as shown

SEQ.ID.NO.:1, SEQ.ID.NO.:3 or SEQ.ID.NO.:5. Regulatory sequences operatively linked to the antisense nucleic acid can be chosen which direct the continuous expression of the antisense RNA molecule.

The recombinant expression vectors of the invention may also contain a
5 selectable marker gene which facilitates the selection of host cells transformed or transfected with a recombinant molecule of the invention. Examples of selectable marker genes are genes encoding a protein such as G418 and hygromycin which confer resistance to certain drugs, β -galactosidase, chloramphenicol acetyltransferase, or firefly luciferase. Transcription of the selectable marker gene is monitored by changes in the concentration of
10 the selectable marker protein such as β -galactosidase, chloramphenicol acetyltransferase, or firefly luciferase. If the selectable marker gene encodes a protein conferring antibiotic resistance such as neomycin resistance transformant cells can be selected with G418. Cells that have incorporated the selectable marker gene will survive, while the other cells die. This makes it possible to visualize and assay for expression of recombinant expression
15 vectors of the invention and in particular to determine the effect of a mutation on expression and phenotype. It will be appreciated that selectable markers can be introduced on a separate vector from the nucleic acid of interest.

The recombinant expression vectors may also contain genes which encode a fusion moiety which provides increased expression of the recombinant protein; increased
20 solubility of the recombinant protein; and aid in the purification of a target recombinant protein by acting as a ligand in affinity purification. For example, a proteolytic cleavage site may be added to the target recombinant protein to allow separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein.

Recombinant expression vectors can be introduced into host cells to produce a
25 transformant host cell. The term "transformant host cell" is intended to include prokaryotic and eukaryotic cells which have been transformed or transfected with a recombinant expression vector of the invention. The terms "transformed with", "transfected with", "transformation" and "transfection" are intended to encompass introduction of nucleic acid (e.g. a vector) into a cell by one of many possible techniques known in the art.
30 Prokaryotic cells can be transformed with nucleic acid by, for example, electroporation or calcium-chloride mediated transformation. Nucleic acid can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofectin, electroporation or microinjection. Suitable methods for transforming and transfecting host cells can be found in
35 Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.

Suitable host cells include a wide variety of prokaryotic and eukaryotic host cells. For example, the proteins of the invention may be expressed in bacterial cells such as

E. coli, insect cells (using baculovirus), yeast cells or mammalian cells. Other suitable host cells can be found in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1991).

The proteins of the invention may also be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964, J. Am. Chem. Assoc. 85:2149-2154) or synthesis in homogenous solution (Houbenweyl, 1987, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart).

III. APPLICATIONS

A. Diagnostic Applications

As previously mentioned, the present inventors have isolated and sequenced a novel gene EPM2A and have shown that it is deleted or mutated in people with Lafora's disease. As a result, the present invention also includes a method of detecting Lafora's disease by detecting a mutation or deletion in the Lafora's disease gene or protein.

i) Detecting Mutations in the Nucleic Acid Sequence

In one embodiment, the present invention provides a method for detecting Lafora's disease comprising detecting a deletion or mutation in the Lafora's disease gene in a sample obtained from an animal, preferably a mammal, more preferably a human. Preferably, the invention provides a method of detecting Lafora's disease comprising detecting a deletion or mutation in the Lafora's disease gene in the region between markers D6S1003 and D6S1042.

The Examples and Tables 1 to 3 summarize some of the mutations found in EPM2A in patient's with Lafora's Disease. Screening assays can be developed for each of the mutations. Details of screening assays that may be employed for the 3 common mutations are provided in Example 3.

One of the common EPM2A mutations is a C → T nonsense mutation of the second base pair of exon 4 found at position 721 in Figure 13. This mutation destroys the recognition site for the restriction enzyme *HaeIII*. Accordingly, the C to T mutation can be detected in a sample by a method comprising:

(a) amplifying the nucleic acid sequences in the sample with primers H1F (5'-GAATGCTCTTTCCACTTTGC-3') and PTPR (5'-GGCTCCTTAGGGAAATCAG-3') in a polymerase chain reaction;

(b) digesting the amplified sequences with the restriction endonuclease *HaeIII*; and

(c) determining the size of the digested sequences wherein the presence of a fragment of approximately 199bp indicates the sample is from an animal with Lafora's disease or an animal that is a carrier of Lafora's disease.

Another common mutation in EMP2A is a G → A mutation of base pair 115 in exon 4 (position 836 in Figure 13). This mutation creates a new *PstI* restriction site in the 520bp DNA fragment that is amplified by primers H1F and PTPR, which is not found in normal, non-carrier individuals. Consequently, the present invention provides a method for detecting a G to A mutation in EMP2A by a method comprising:

(a) amplifying the nucleic acid sequences in the sample with primers H1F (5'-GAATGCTCTTTCCACTTTGC-3') and PTPR (5'-GGCTCCTTAGGGAAATCAG-3') in a polymerase chain reaction;

(b) digesting the amplified sequences with the restriction endonuclease *PstI*;
and

(c) determining the size of the digested sequences wherein the presence of at least one fragment of approximately 520bp indicates that the sample is from an animal that does not have Lafora's disease or an animal that is a carrier of Lafora's disease. Persons with Lafora's disease will have two variant bands of 195 base pairs and 350 base pairs.

Many families with Lafora's disease have deletions of EMP2A. Patients homozygous for these deletions can be detected by the absence of PCR amplification products using primers JRGXBF/JRGXBR which amplify the deleted region. Consequently, the present invention includes a method for determining a deletion in the EMP2A gene by a method comprising:

(a) amplifying the nucleic acid sequences in the sample with primers JRGXBF (5' - T C C A T T G T G C T A A T G C T A T C T C - 3') a n d J R G X B R (5'-TCAGCTTGCTTTGAGGATATTT-3') in a polymerase chain reaction; and

(b) detecting amplified sequence wherein the absence of an amplified sequence indicates that the sample is from an animal with Lafora's disease.

One skilled in the art will appreciate that other methods, in addition to the ones discussed above and in the examples, can be used to detect mutations in the EMP2A gene. For example, in order to isolate nucleic acids from the Lafora's disease gene in a sample, one can prepare nucleotide probes from the nucleic acid sequences of the invention. In addition, the nucleic acid probes described herein (for example, see Figure 1) can also be used. A nucleotide probe may be labelled with a detectable marker such as a radioactive label which provides for an adequate signal and has sufficient half life such as ³²P, ³H, ¹⁴C or the like. Other detectable markers which may be used include antigens that are recognized by a specific labelled antibody, fluorescent compounds, enzymes, antibodies specific for a labelled antigen, and chemiluminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization.

Accordingly, the present invention also relates to a method of detecting the presence of a nucleic acid molecule from the EPM2A gene in a sample comprising contacting the sample under hybridization conditions with one or more of nucleotide probes which hybridize to the nucleic acid molecules and are labelled with a detectable marker, and
5 determining the degree of hybridization between the nucleic acid molecule in the sample and the nucleotide probes. Preferably, the nucleic acid probes hybridize with a portion of the EPM2A gene containing a mutation site in Lafora's disease, for example, in the region between marker DS61003 and DS61042.

Hybridization conditions which may be used in the methods of the invention
10 are known in the art and are described for example in Sambrook J, Fritsch EF, Maniatis T. In: Molecular Cloning, A Laboratory Manual, 1989. (Nolan C, Ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. The hybridization product may be assayed using techniques known in the art. The nucleotide probe may be labelled with a detectable marker as described herein and the hybridization product may be assayed by detecting the
15 detectable marker or the detectable change produced by the detectable marker.

Prior to hybridizing a sample with DNA probes, the sample can be treated with primers that flank the EPM2A gene in order to amplify the nucleic acid sequences in the sample. The primers used may be the ones described in the present application. For example, primers specific for the transcript A include 266F and GSP3. Primers for the
20 transcript B include AA490925F and AA490925R. In addition, the sequence of the EPM2A gene provided herein also permits the identification and isolation, or synthesis of new nucleotide sequences which may be used as primers to amplify a nucleic acid molecule of the invention, for example in the polymerase chain reaction (PCR) which is discussed in more detail below. The primers may be used to amplify the genomic DNA of other species. The
25 PCR amplified sequences can be examined to determine the relationship between the genes of various species.

The length and bases of the primers for use in the PCR are selected so that they will hybridize to different strands of the desired sequence and at relative positions along the sequence such that an extension product synthesized from one primer when it is
30 separated from its template can serve as a template for extension of the other primer into a nucleic acid of defined length. Primers which may be used in the invention are oligonucleotides i.e. molecules containing two or more deoxyribonucleotides of the nucleic acid molecule of the invention which occur naturally as in a purified restriction endonuclease digest or are produced synthetically using techniques known in the art such as
35 for example phosphotriester and phosphodiester methods (See Good et al Nucl. Acid Res 4:2157, 1977) or automated techniques (See for example, Conolly, B .A. Nucleic Acids Res. 15:15(7): 3131, 1987). The primers are capable of acting as a point of initiation of synthesis when placed under conditions which permit the synthesis of a primer extension product

which is complementary to the DNA sequence of the invention i.e. in the presence of nucleotide substrates, an agent for polymerization such as DNA polymerase and at suitable temperature and pH. Preferably, the primers are sequences that do not form secondary structures by base pairing with other copies of the primer or sequences that form a hair pin configuration. The primer preferably contains between about 7 and 25 nucleotides.

The primers may be labelled with detectable markers which allow for detection of the amplified products. Suitable detectable markers are radioactive markers such as P-32, S-35, I-125, and H-3, luminescent markers such as chemiluminescent markers, preferably luminol, and fluorescent markers, preferably dansyl chloride, fluorescein-5-isothiocyanate, and 4-fluor-7-nitrobenz-2-axa-1,3 diazole, enzyme markers such as horseradish peroxidase, alkaline phosphatase, β -galactosidase, acetylcholinesterase, or biotin.

It will be appreciated that the primers may contain non-complementary sequences provided that a sufficient amount of the primer contains a sequence which is complementary to a nucleic acid molecule of the invention or oligonucleotide fragment thereof, which is to be amplified. Restriction site linkers may also be incorporated into the primers allowing for digestion of the amplified products with the appropriate restriction enzymes facilitating cloning and sequencing of the amplified product.

In an embodiment of the invention a method of determining the presence of a nucleic acid molecule of the invention is provided comprising treating the sample with primers which are capable of amplifying the nucleic acid molecule or a predetermined oligonucleotide fragment thereof in a polymerase chain reaction to form amplified sequences, under conditions which permit the formation of amplified sequences and, assaying for amplified sequences.

The polymerase chain reaction refers to a process for amplifying a target nucleic acid sequence as generally described in Innis et al, Academic Press, 1990 in Mullis et al., U.S. Pat. No. 4,863,195 and Mullis, U.S. Patent No. 4,683,202 which are incorporated herein by reference. Conditions for amplifying a nucleic acid template are described in M.A. Innis and D.H. Gelfand, PCR Protocols, A Guide to Methods and Applications M.A. Innis, D.H. Gelfand, J.J. Sninsky and T.J. White eds, pp3-12, Academic Press 1989, which is also incorporated herein by reference.

The amplified products can be isolated and distinguished based on their respective sizes using techniques known in the art. For example, after amplification, the DNA sample can be separated on an agarose gel and visualized, after staining with ethidium bromide, under ultra violet (UV) light. DNA may be amplified to a desired level and a further extension reaction may be performed to incorporate nucleotide derivatives having detectable markers such as radioactive labelled or biotin labelled nucleoside triphosphates. The primers may also be labelled with detectable markers as

discussed above. The detectable markers may be analyzed by restriction and electrophoretic separation or other techniques known in the art.

The conditions which may be employed in the methods of the invention using PCR are those which permit hybridization and amplification reactions to proceed in the presence of DNA in a sample and appropriate complementary hybridization primers. Conditions suitable for the polymerase chain reaction are generally known in the art. For example, see M.A. Innis and D.H. Gelfand, PCR Protocols, A guide to Methods and Applications M.A. Innis, D.H. Gelfand, J.J. Sninsky and T.J. White eds, pp3-12, Academic Press 1989, which is incorporated herein by reference. Preferably, the PCR utilizes polymerase obtained from the thermophilic bacterium *Thermus aquaticus* (Taq polymerase, GeneAmp Kit, Perkin Elmer Cetus) or other thermostable polymerase may be used to amplify DNA template strands.

It will be appreciated that other techniques such as the Ligase Chain Reaction (LCR) and NASBA may be used to amplify a nucleic acid molecule of the invention (Barney in "PCR Methods and Applications", August 1991, Vol.1(1), page 5, and European Published Application No. 0320308, published June 14, 1989, and U.S. Serial NO. 5,130,238 to Malek).

(ii) Detecting the Laforin Protein

In another embodiment, the present invention provides a method for detecting Lafora's disease comprising determining if the Laforin protein is present in a sample from an animal.

The Laforin protein of the present invention may be detected in a biological sample using antibodies that are specific for Laforin using various immunoassays that are discussed below.

Conventional methods can be used to prepare the antibodies. For example, by using a peptide from the Laforin protein of the invention, polyclonal antisera or monoclonal antibodies can be made using standard methods. A mammal, (e.g., a mouse, hamster, or rabbit) can be immunized with an immunogenic form of the peptide which elicits an antibody response in the mammal. Techniques for conferring immunogenicity on a peptide include conjugation to carriers or other techniques well known in the art. For example, the peptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassay procedures can be used with the immunogen as antigen to assess the levels of antibodies. Following immunization, antisera can be obtained and, if desired, polyclonal antibodies isolated from the sera.

To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an immunized animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells. Such

techniques are well known in the art, (e.g., the hybridoma technique originally developed by Kohler and Milstein (Nature 256, 495-497 (1975)) as well as other techniques such as the human B-cell hybridoma technique (Kozbor et al., Immunol. Today 4, 72 (1983)), the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al. Monoclonal
5 Antibodies in Cancer Therapy (1985) Allen R. Bliss, Inc., pages 77-96), and screening of combinatorial antibody libraries (Huse et al., Science 246, 1275 (1989)). Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with the peptide and the monoclonal antibodies can be isolated. Therefore, the invention also contemplates hybridoma cells secreting monoclonal antibodies with specificity for a
10 protein of the invention.

The term "antibody" as used herein is intended to include fragments thereof which also specifically react with a protein, of the invention, or peptide thereof. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above. For example, F(ab')₂ fragments can be
15 generated by treating antibody with pepsin. The resulting F(ab')₂ fragment can be treated to reduce disulfide bridges to produce Fab' fragments.

Chimeric antibody derivatives, i.e., antibody molecules that combine a non-human animal variable region and a human constant region are also contemplated within the scope of the invention. Chimeric antibody molecules can include, for example, the
20 antigen binding domain from an antibody of a mouse, rat, or other species, with human constant regions. Conventional methods may be used to make chimeric antibodies containing the immunoglobulin variable region which recognizes a CipA protein (See, for example, Morrison et al., Proc. Natl Acad. Sci. U.S.A. 81,6851 (1985); Takeda et al., Nature 314, 452 (1985), Cabilly et al., U.S. Patent No. 4,816,567; Boss et al., U.S. Patent
25 No. 4,816,397; Tanaguchi et al., European Patent Publication EP171496; European Patent Publication 0173494, United Kingdom patent GB 2177096B).

Monoclonal or chimeric antibodies specifically reactive with a protein of the invention as described herein can be further humanized by producing human constant region chimeras, in which parts of the variable regions, particularly the conserved framework
30 regions of the antigen-binding domain, are of human origin and only the hypervariable regions are of non-human origin. Such immunoglobulin molecules may be made by techniques known in the art, (e.g., Teng et al., Proc. Natl. Acad. Sci. U.S.A., 80, 7308-7312 (1983); Kozbor et al., Immunology Today, 4, 7279 (1983); Olsson et al., Meth. Enzymol., 92, 3-16 (1982)), and PCT Publication WO92/06193 or EP 0239400). Humanized antibodies can also
35 be commercially produced (Scotgen Limited, 2 Holly Road, Twickenham, Middlesex, Great Britain.)

Specific antibodies, or antibody fragments, reactive against a protein of the invention may also be generated by screening expression libraries encoding immunoglobulin genes, or portions thereof, expressed in bacteria with peptides produced from the nucleic acid molecules of the present invention. For example, complete Fab fragments, VH regions and FV regions can be expressed in bacteria using phage expression libraries (See for
5 example Ward et al., Nature 341, 544-546: (1989); Huse et al., Science 246, 1275-1281 (1989); and McCafferty et al. Nature 348, 552-554 (1990)).

Antibodies may also be prepared using DNA immunization. For example, an expression vector containing a nucleic acid of the invention (as described above) may be
10 injected into a suitable animal such as mouse. The protein of the invention will therefore be expressed *in vivo* and antibodies will be induced. The antibodies can be isolated and prepared as described above for protein immunization.

The antibodies may be labelled with a detectable marker including various enzymes, fluorescent materials, luminescent materials and radioactive materials.
15 Examples of suitable enzymes include horseradish peroxidase, biotin, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; and examples of suitable radioactive material
20 include S-35, Cu-64, Ga-67, Zr-89, Ru-97, Tc-99m, Rh-105, Pd-109, In-111, I-123, I-125, I-131, Re-186, Au-198, Au-199, Pb-203, At-211, Pb-212 and Bi-212. The antibodies may also be labelled or conjugated to one partner of a ligand binding pair. Representative examples include avidin-biotin and riboflavin-riboflavin binding protein. Methods for conjugating or labelling the antibodies discussed above with the representative labels set forth above
25 may be readily accomplished using conventional techniques.

The antibodies reactive against proteins of the invention (e.g. enzyme conjugates or labelled derivatives) may be used to detect a protein of the invention in various samples, for example they may be used in any known immunoassays which rely on the binding interaction between an antigenic determinant of a protein of the invention and
30 the antibodies. Examples of such assays are radioimmunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immuno-precipitation, latex agglutination, hemagglutination, and histochemical tests. Thus, the antibodies may be used to identify or quantify the amount of a protein of the invention in a sample in order to diagnose the presence of Lafora's disease.

35 In a method of the invention a predetermined amount of a sample or concentrated sample is mixed with antibody or labelled antibody. The amount of antibody used in the process is dependent upon the labelling agent chosen. The resulting protein bound to antibody or labelled antibody may be isolated by conventional isolation

techniques, for example, salting out, chromatography, electrophoresis, gel filtration, fractionation, absorption, polyacrylamide gel electrophoresis, agglutination, or combinations thereof.

The sample or antibody may be insolubilized, for example, the sample or
5 antibody can be reacted using known methods with a suitable carrier. Examples of suitable carriers are Sepharose or agarose beads. When an insolubilized sample or antibody is used protein bound to antibody or unreacted antibody is isolated by washing. For example, when the sample is blotted onto a nitrocellulose membrane, the antibody bound to a protein of the invention is separated from the unreacted antibody by washing with a buffer, for example,
10 phosphate buffered saline (PBS) with bovine serum albumin (BSA).

When labelled antibody is used, the presence of Laforin can be determined by measuring the amount of labelled antibody bound to a protein of the invention in the sample or of the unreacted labelled antibody. The appropriate method of measuring the labelled material is dependent upon the labelling agent.

15 When unlabelled antibody is used in the method of the invention, the presence of Laforin can be determined by measuring the amount of antibody bound to the protein using substances that interact specifically with the antibody to cause agglutination or precipitation. In particular, labelled antibody against an antibody specific for a protein of the invention, can be added to the reaction mixture. The presence of a protein of the
20 invention can be determined by a suitable method from among the already described techniques depending on the type of labelling agent. The antibody against an antibody specific for a protein of the invention can be prepared and labelled by conventional procedures known in the art which have been described herein. The antibody against an antibody specific for a protein of the invention may be a species specific
25 anti-immunoglobulin antibody or monoclonal antibody, for example, goat anti-rabbit antibody may be used to detect rabbit antibody specific for a protein of the invention.

(iii) Kits

The reagents suitable for carrying out the methods of the invention may be packaged into convenient kits providing the necessary materials, packaged into suitable
30 containers. Such kits may include all the reagents required to detect a nucleic acid molecule or protein of the invention in a sample by means of the methods described herein, and optionally suitable supports useful in performing the methods of the invention.

In one embodiment of the invention, the kit includes primers which are capable of amplifying a nucleic acid molecule of the invention or a predetermined oligonucleotide
35 fragment thereof, all the reagents required to produce the amplified nucleic acid molecule or predetermined fragment thereof in the polymerase chain reaction, and means for assaying the amplified sequences. The kit may also include restriction enzymes to digest the PCR products. In another embodiment of the invention the kit contains a nucleotide

probe which hybridizes with a nucleic acid molecule of the invention, reagents required for hybridization of the nucleotide probe with the nucleic acid molecule, and directions for its use. In a further embodiment of the invention the kit includes antibodies of the invention and reagents required for binding of the antibody to a protein of the invention in a sample.

5 The methods and kits of the present invention may be used to detect Lafora's disease. Samples which may be tested include bodily materials such as blood, urine, serum, tears, saliva, feces, tissues, cells and the like. In addition to human samples, samples may be taken from mammals such as non-human primates, etc.

10 Before testing a sample in accordance with the methods described herein, the sample may be concentrated using techniques known in the art, such as centrifugation and filtration. For the hybridization and/or PCR-based methods described herein, nucleic acids may be extracted from cell extracts of the test sample using techniques known in the art.

B. Therapeutic Applications

15 As mentioned previously, the nucleic acid molecules of the present invention are deleted or mutated in people with Lafora's disease. Accordingly, the present invention provides a method of treating or preventing Lafora's disease by administering a nucleic acid sequence containing a sufficient portion of the EPM2A gene to treat or prevent Lafora's disease.

20 Recombinant molecules comprising a nucleic acid sequence or fragment thereof, may be directly introduced into cells or tissues *in vivo* using delivery vehicles such as retroviral vectors, adenoviral vectors and DNA virus vectors. They may also be introduced into cells *in vivo* using physical techniques such as microinjection and electroporation or chemical methods such as coprecipitation and incorporation of DNA into liposomes.

25 Recombinant molecules may also be delivered in the form of an aerosol or by lavage.

 The nucleic acid sequences may be formulated into pharmaceutical compositions for administration to subjects in a biologically compatible form suitable for administration *in vivo*. By "biologically compatible form suitable for administration *in vivo*" is meant a form of the substance to be administered in which any toxic effects are outweighed by the

30 therapeutic effects. The substances may be administered to living organisms including humans, and animals. Administration of a therapeutically active amount of the pharmaceutical compositions of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of a substance may vary according to factors such as the

35 disease state, age, sex, and weight of the individual, and the ability of antibody to elicit a desired response in the individual. Dosage regima may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or

the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

The active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.

The compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the substances in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

C. Experimental Models

The present invention also includes methods and experimental models for studying the function of the EPM2A gene and Laforin protein. Cells, tissues and non-human animals that lack the EPM2A gene or partially lack in Laforin expression may be developed using recombinant expression vectors having a specific deletion or mutation in the EPM2A gene. A recombinant expression vector may be used to inactivate or alter the EPM2A gene by homologous recombination and thereby create an EPM2A deficient cell, tissue or animal.

Null alleles may be generated in cells, such as embryonic stem cells by deletion mutation. A recombinant EPM2A gene may also be engineered to contain an insertion mutation which inactivates EPM2A. Such a construct may then be introduced into a cell, such as an embryonic stem cell, by a technique such as transfection, electroporation, injection etc. Cells lacking an intact EPM2A gene may then be identified, for example by Southern blotting, Northern Blotting or by assaying for EPM2A using the methods described herein. Such cells may then be fused to embryonic stem cells to generate transgenic non-human animals deficient in EPM2A. Germline transmission of the mutation may be achieved, for example, by aggregating the embryonic stem cells with early stage embryos, such as 8 cell embryos, *in vitro*; transferring the resulting blastocysts into recipient females and; generating germline transmission of the resulting aggregation chimeras. Such a mutant animal may be used to define specific cell populations, developmental patterns and *in vivo* processes, normally dependent on EPM2A expression. The present invention also includes the preparation of tissue specific knock-outs of the EPM2A gene.

The following non-limiting examples are illustrative of the present invention:

EXAMPLES

EXAMPLE 1

Characterization of EPM2A

5 Materials and Methods

Patients. The diagnosis of Lafora's disease in patients with teenage onset progressive myoclonus epilepsy was confirmed by demonstration of Lafora bodies in skin, liver, muscle or brain biopsies (6-9) in at least one affected member from each of 38 families included in this study.

10 **Physical mapping.** Using mapping data available from the Whitehead Institute/MIT Genome Center (<http://mit-genome.wi.mit.edu/>) as well as by identifying additional clones it was possible to establish an overlapping set of yeast artificial chromosome (YAC) clones between D6S1003 and D6S311. A total of 136 markers (12 genes, 41 ESTs, and 83 STSs/probes) were assayed against the YAC contig and 32 of these were
15 found to be in the EPM2A critical region (Figure 1). We also isolated 129 P1-derived artificial chromosomes (PACs) which cover an estimated 90% of the region between D6S1003 and D6S311 and have aligned the PACs by probe content, restriction mapping, as well fingerprint analysis. Information on all DNA markers can be found at the Genome
20 DataBase (<http://www.gdbwww.gdb.org/>) or the Sanger Genome Center WWW site (<http://www.sanger.ac.uk/HGP/Chr6/>).

Figure 1 illustrates the physical map of the Lafora's disease critical region. (A). A yeast artificial chromosome (YAC) contig was established covering the 1.5 Mb critical region between D6S1003 and D6S311. The presence of a DNA marker on a YAC clone is shown by a corresponding vertical bar. The markers that are highlighted with a circle
25 and a square represent genetic markers or ESTs, respectively, while the remaining ones are unique landmarks (STSs). The region between D6S1003 and D6S1042 that demonstrated an extended region of homozygosity in affected members of a previously uncharacterized family is shown by a thicker horizontal bar and this is the new EPM2A critical region (see Figure 2A); (B). A P1-derived artificial chromosome (PAC) map encompassing the
30 immediate region surround D6S1703. The extent of the deletion could be defined by PCR analysis of mapped STSs (see Figure 2B). LDCR4 represents a transcript of unidentified function and EPM2A is the Lafora disease gene. Since the 5'-end of this gene is not yet known it is represented with a dashed line.

Northern blots, cDNA library screening, and RACE. Multiple-tissue (cat.
35 #7760-1) and Human Brain II (cat. #7755-1) Northern blots were purchased from Clontech and hybridization was carried out as recommended by the supplier. The transcript A specific probe was generated using PCR primers 266F (5'-CGGCACGAGGATTATTCAAG-3') and GSP3 (5'-GCTCGGGTACTGAGGTCTG-3') which amplified an 190 bp fragment from

cDNA clone 266552 (Figure 3). The transcript B specific probe was derived using PCR primers AA490925F (5'-AGTTGTTACACAGGGTTGTTGG-3') and AA490925R (5'-AGGCTGTACATCAGACAGAAGG-3') which amplified an 373 bp segment from cDNA SFB14 (Figure 3). We have sequenced the HTF-island shown in Figure 1B at the 5'-end of

5 EPM2A.

Genotyping. Haplotypes for 6q23-25 were constructed for all family members using microsatellite markers at loci D6S314, D6S1704, D6S1003, D6S1010, D6S1049, D6S1703, D6S1042, D6S1649, D6S978, D6S311 and D6S1637. Primer sequences were obtained from Genethon or from the Cooperative Human Linkage Centre. PCR conditions have been reported previously (13). PCR products were separated on polyacrylamide gels. In 8 families (20%), haplotype analyses revealed evidence against linkage to 6q23-25. Of the remaining 30 LD families 16 reported a history of consanguinity. Thirty-one of these families have been described previously (refs. 12, 13, 25, 25).

Mutation Analysis. Mutations were detected by radioactive cycle sequencing using the Thermosequenase Kit (Amersham Life Science) with Qiagen column purified PCR products. The combinations of PCR primer pairs used were JRGXBCF (5'-TCCATTGTGCTAATGCTATCTC-3') and JRGXBCR (5'-TCAGCTTGCTTTGAGGATATTT-3'); product size 310 bp, 824F (5'-GCCGAGTACAGATGCTGCC-3') and 824R (5'-CACACAGTCCTTTTCAGTTCAGG-3'); product size 384 bp, and H1F (5'-GAATGCTCTTTCCACTTTGC-3') and 824R; product size 587 bp. The position of the primers are shown in Figure 3.

Characterization of Lafora's Disease Gene

To characterize the extent of the homozygous deletion in the affected in LD-L4 a P1-derived artificial chromosome (PAC) contig extending outwards from D6S1703 was constructed. It could be determined that the deletion encompassed approximately 50 kb and that it did not interrupt directly the LDCR4 transcription unit (Figure 1B). PAC clones 365C1, 466P17 and 28H5 (which encompassed the deletion) were sequenced in order to identify new candidate transcription units (Figure 1B). A segment of DNA (E42) located within the deletion detected a single EST (clone 743381) in the database (Figure 3). DNA sequencing of this cDNA indicated it contained a segment of identity with one other EST (266552). This EST, however, was aligned previously with others into separate groups (or Unigenes named Hs.22464 and Hs.112229). Subsequently, we used clone 743381 and 824559 and PCR primers derived from their sequence for screening of multiple cDNA libraries in an attempt to clone the entire coding region of this gene.

Figure 2 shows a refined mapping of the Lafora disease gene. (A) Pedigrees and genotype data are provided for Lafora family LD39. Individuals affected (solid) or unaffected (open) with Lafora disease are indicated. Below each individual is the corresponding genotype data (the markers are listed in their order from centromere (top) to

telomere (bottom) as determined using the physical map shown in Figure 1). The boxed segments of the haplotypes indicate regions of homozygosity. The loci in bold indicate the previous LD critical region. (B) Detection of 2 markers (D6S1703 and 109F4.E05.5) determined to be absent by PCR in the affected members of the consanguineous Lafora family LD-L4.

Figure 3 shows overlapping cDNA clones aligned with genomic DNA segments. The portions of each cDNA clone for which there was sequence is represented with a box. The corresponding genomic fragments are shown as stippled boxes below. The clones preceded with an (E) and (H) represent EcoRI and HindIII fragments, respectively. The positions of the primers used for mutation screening are shown as is the site of the phosphatase domain and the stop codon (*).

Through analysis of the alignment of the DNA sequences of all of the EST clones as well as the newly identified cDNAs, at least 4 putative types of transcripts that corresponded to *EPM2A* could be defined (named transcript A, B, C, and D (Figure 3). The cDNAs grouped into transcript A could be categorized based on regions of sequence identity at their 3'-ends. A consensus sequence was compiled and it was found to be distributed amongst 4 exons spanning approximately 130 kb (Figs. 1A and 3). A single cDNA (266552) representing transcript B shared exact identity with transcript A except for the omission of a 1,700 bp segment due to splicing (Figs. 3 and 4). By comparing the corresponding genomic regions to the cDNAs a common origin for transcript A and B could be verified suggesting they are alternative forms of the same gene, the gene-products, of which, would be predicted to have unique carboxyl-terminal amino acid sequences (Figure 4B).

Figure 4 shows the nucleotide sequence of cDNA encoding the *EPM2A* gene together with the predicted amino acid sequence. (A) The consensus nucleotide sequence was derived from the cDNA clones 266552, RACE-A, RACE-B, RACE-C, and RACE-D shown in Figure 3. The position of the mutations identified are indicated. The (*) indicates a stop mutation site and the position of 2 known splice junctions is shown by the horizontal arrows. An A to T polymorphism which is present in approximately 40-50% of the population is shown; (B) the deduced C terminus of transcript A compared with transcript B. The latter arises due to the removal by splicing of nt 738-2508 (Figure 3 and Figure 4A), which would be predicted to generate an isoform with a unique 3' end. At the present time, transcript B is known to extend to position 94 of the predicted amino acid sequence shown (Figure 4A). Transcript C (cDNA SFB14) is described elsewhere (C), the putative PTP active sites of *EPM2A*, *MTM1*, *PTEN*, *PTP18*, *dPTP61F* and viral PTP. The shaded amino acids (C and R) represent catalytic residues. On the basis of sequence analysis alone, laforin predicts an intracellular PTP with dual specificity phosphatase activity.

The inventors determined a partial map (Figure 3) and sequenced the corresponding genomic regions that contained nucleotide identity to these segments to prove

their common origin. The results suggest that transcript A, B, C and D are indeed alternatively spliced forms of the same gene. The consensus sequence presently compiled for transcript A was distributed amongst at least 4 exons spanning greater than 50 kb while transcript B was represented as a contiguous segment of DNA. A single EST clone, 743381, which represents another alternatively spliced form that appeared to be most common to transcript A was also identified (Figure 3A). It contained at least 8 exons (Figure 3) but a significant open reading frame was not detected. The newly identified gene, EPM2A, which encodes Laforin, was the only one determined to be deleted in family LD-L4 (Figure 1).

Two other single cDNA clones, SFB14 and 743381, which could represent additional alternative forms of *EPM2A*, were also identified (Figure 3). SFB14 was contiguous to genomic DNA and identical to the 3'-end of transcript A except its open reading frame (ORF) was predicted to extend 48 amino acids 5' into the last intron shown in Figure 3. Clone 743381 contained 8 exons with appropriate exon-intron boundaries (Figure 3) but its significance could not be assessed due to the lack of continuous open reading frame.

In addition to the essential cysteine and arginine residues found in all PTPs (Figure 4C), *EPM2A* contains an aspartic acid positioned 31 residues amino-terminal of the cysteine nucleophile. This amino acid is important for catalysis as it is located on a loop that undergoes conformational change when substrate is bound to enzyme.

The corresponding mRNA for *EPM2A* was determined to be 3200 nucleotides in length in multiple tissues based on RNA gel-blot hybridization experiments. Figure 5 shows RNA expression pattern of the Laforin gene. Northern blot analysis in different tissues as indicated at the top. The probes used are described in the Materials and Methods and the exposure time was 4 days at -80°C. The *EPM2A* message is observed in all tissues tested and the apparent overexpression in heart and skeletal muscle is due to overloading of mRNA in these lanes as was seen when using any gene-specific probe. The results of Figure 5 illustrate that strong hybridization signals were detected in skeletal muscle RNA and clear signals were also seen in heart, brain, placenta, lung, liver, kidney and pancreas. In addition, the same size mRNA was detected in cerebellum, cerebral cortex, medulla, spinal cord, occipital pole, frontal lobe, temporal lobe, and putamen. Identical results showing the same 3200 nucleotide message and tissue distribution were observed when a DNA probe believed to be specific for each isoform of the gene based on the established consensus sequences, was used. For example, a probe derived from the 3'-UTR region of transcript B of *EPM2A* was determined unequivocally to be specific for this isoform. For transcript A, the probe was generated from the unique region shown in Figure 4A and RT-PCR experiments seemed to confirm the specificity of this fragment (data not shown). On the basis of northern-blot results and the relative number of ESTs identified, it is probable that transcript A represents the major isoform of *EPM2A*, and that it corresponds to the

3.2kb mRNA. From the analysis of the genomic DNA sequence, we have identified an additional ORF at the HTF-island (Figure 3). As this predicted exon has all the proposed features of the consensus sequence of a eukaryotic translation initiation site, and 113 nt of it are represented in the consensus cDNA sequence, it could represent the 5' end of EPM2A.

5 The protein encoded by EPM2A contains an amino acid motif (Figure 1C) that corresponds with the consensus sequence, HcxxGxxRS(T), of the catalytic site of PTPs. In addition to the essential cysteine and arginine residues found in all PTPs (Figure 4C), EPM2A contains the expected aspartic acid necessary for completion of the catalytic reaction, positioned 31-aa N terminal of the cysteine nucleophile.

10 In an attempt to isolate the remainder of the coding region for these transcripts we performed multiple rounds of 5'-RACE on total brain and poly(A)+ mRNA which has allowed us to extend transcript A (but not transcript B) further. Beyond the most 5'-sequences shown in Figure 4, however, all of the RACE clones recovered seemed to share the expected DNA sequences but then diverged in different ways that did not allow for a
15 common consensus to be established. However, comparative DNA sequence analysis of the human EPM2A gene its corresponding mouse homolog (also called EPMA) confirmed the full length gene sequence as shown in Figure 13.

20 The deduced amino acid sequence of the newly identified protein(s) indicated that transcripts A, B, C and D encode a 9 amino acid motif (Figure 4A) that corresponds exactly to the consensus sequence, HCxxGxxRS(T), of the active catalytic site of protein tyrosine phosphatases (PTPs) (14,15). So far, no other structural motifs could be identified, and from the sequence it is not apparent if this protein belongs to the receptor-like PTPs, the intracellular PTPs, or the dual specificity phosphatases (DSPs) which dephosphorylate both tyrosine and serine/threonine residues (16). The identification of
25 the EPM2A gene as a putative PTP provides the first clue to understand the basic defect.

30 At the HTF-island shown in Figure 3, we have identified through GRAIL analysis (<http://compbio.ornl.gov>) an additional putative exon 189 nucleotides in length. An ATG (AUG) triplet is present at the beginning of this predicted ORF and the nucleotide sequence surrounding the consensus sequence (CCCGCCAUGC) has the proposed features of the consensus sequence (GCCA/GCCAUGG) of a eukaryotic translation initiation site (12). The predicted start exon maintains open reading frame with the most 5' sequence of transcript A and this combined stretch of 298 nucleotides contains exon/intron junction sequences with splice sites that confirm with the consensus in other mammalian genes. If the predicted exon is part of EPM2A, transcript A would be predicted to be 317 amino acids
35 long.

EXAMPLE 2

EPM2A Mutations

Using the available genomic structure for the gene, the inventors' screened an affected member from each of 30 Lafora families for mutations by direct DNA sequencing.

- 5 A total of 14 mutations were detected consisting of 12 different DNA sequence alterations and 2 microdeletions. The mutations are summarized in Table 3. The mutation from C to A at position -12 refers to a mutation that occurs 12 bases upstream from the ATG start codon in Figure 13. Some of the sequence upstream of the ATG is as follows:

... gcccggtattcgccgCcgccgccATG...

- 10 The mutation site at -12 is indicated with a capital C. To date, mutations have been found in 65% of EPM2A families. Some of the mutations are discussed below.

- Two mutations that, based on the current consensus sequences were specific for transcript A, could be detected. Family LD-5 contained a homozygous C to T point mutation which resulted in an arginine to cysteine change affecting a region of unknown function. To
15 test for the presence of the C to T point mutation in family LD-5 in the unaffected population PCR was completed on 54 samples (108 chromosomes) using JRGXBF and JRGXBR primers and the product was blotted in duplicate. One membrane was hybridized with a wild type oligonucleotide (ATCATGACCGTTGCTGTAC) and the other with LD5 mutant (TCATCATGACTGTTGCTGTAC) oligonucleotide at 42°C (washing with 5X SSC at room
20 temperature for 20 minutes followed by 2X SSC 20 minutes at 65°C). No mutant alleles were found.

- The inventors have screened 100 normal chromosomes for this change and no mutant alleles were found. In family I-22 a homozygous G to T non-sense change in a region specific to transcript A would predict premature termination of the EPM2A protein. In
25 sequences common to both isoforms the inventors detected in the consanguineous family EPM2A00-4, a homozygous insertion of an A which would result in a frameshift that would cause an interruption of the tyrosine phosphatase domain. The inventors have identified in 4 consanguineous families a homozygous nonsense mutation which results from a C to T change which causes the introduction of a premature stop codon just preceding the tyrosine
30 phosphatase domain. This same nonsense mutation was found on one chromosome of one additional family (L6) while the other chromosome had a G to A change resulting which results in a glycine to serine non-conservative substitution. Finally, in family LD-33 an A to T transition results in a glutamine to leucine change in a residue located just after the tyrosine phosphatase domain near the carboxy terminus. This mutation, apparently the
35 mildest found, occurs in a family with relative preservation of mental functions and a relatively protracted course (13). The five families having the C to T change are all of Spanish decent indicating this may be the common mutation in this ethnic background.

Figure 6 shows representative mutations found in 2 Lafora's disease families. The left, middle, and right panels show the in-frame sequence of 5 codons surrounding an unaffected non-EPM2A carrier sibling, a EPM2A-carrier parent, and an affected EPM2A individual, respectively. (A) Family LD-16 in which a homozygous C to T transversion results in the introduction of a stop mutation, and (B) Family LD-33 in which a homozygous missense results in a glutamine to cysteine change.

The unraveling of the aetiopathogenesis of Lafora's disease needs to include an understanding of the formation of the pathognomonic Lafora bodies. These unique structures have been found in LD patients in the same tissues in which we have observed EPM2A expression (6-8, and Figure 5). Polyglucosans are unbranched equivalents of glycogen (10). Polyglucosan bodies resembling and sharing common antigenicity with Lafora bodies have been found in glycogen storage disease type IV (Andersen disease) and in the normal corpora amylacea of aged brains (17). Andersen disease has been shown to arise due to mutations in the α -1,4 glucan gene on chromosome 3 which codes for the glycogen branching enzyme (18). It is possible that mutations in a gene that lead to the lack of production of the Laforin tyrosine phosphatase protein could affect the metabolism of glycogen. Both glycogen biosynthesis and breakdown are heavily regulated by phosphokinases and phosphatases (14).

EPM2A has at least two alternate forms (as does *MTM1*) which appear to encode protein isoforms that might be predicted to have different functions or subcellular localizations in a manner analogous to the *Drosophila* PTP, dPTP61F, which also undergoes alternative splicing at the 3' end (24,21). In the case of dPTP61F, it is known that the alternate carboxy termini govern the localization of the protein to either the cytoplasmic membrane or to the nucleus (24).

Although it seems that the accumulations in Lafora bodies are responsible for neuronal death in Lafora's disease, it is not clear whether the epilepsy is secondary to neurodegeneration or is a direct result of abnormal neuronal Laforin expression. In various models, both synaptic transmission and key components of neuronal excitability such as the NMDA type of voltage-gated calcium channels appear to be subject to phosphoregulation (19,20).

With 75 of 500 different potential DSPs and PTPs discovered so far, this evolving family of phosphatases is likely to have as diverse and as important a role in various regulatory processes as its counterpart family of protein tyrosine kinases. Biological functions attributed to these proteins so far include regulation of neuronal adhesion, control of axonal pathfinding, regulation of growth factor, cytokine and oligomeric receptor signaling, and dephosphorylation of MAP Kinases (MAPKs) and other roles in tumor suppression (16). Involvement of members of this phosphatase family in non-neoplastic diseases has been found in only one other human disorder, namely X-linked

myotubular myopathy (21). In this disease, mutations of the DSP MTM1 result in an arrest of muscle maturation in utero after a period of normal development (22).

Laforin is the first member of the family of PTPs and DSPs to be involved in human central nervous system disease. Further investigation will be necessary to understand its role in normal brain, in the formation of Lafora bodies and in Lafora's disease and its epilepsy.

EXAMPLE 3

Summary of Common EPM2A Mutations

Patients and methods

Patients reported here had biopsy-proven Lafora's disease. Polymerase chain reaction (PCR) primer sequences and conditions were: JRGXBF: 5'-TCCATTGTGCTAATGCTATCTC-3', JRGXBR: 5'-TCAGCTTGCTTTGAGGATATTT-3', H1F: 5'-GAATGCTCTTCCACTTTGC-3', PTPR: 5'-GGCTCCTTAGGGAAATCAG-3'; Annealing: 62°; [MgCl₂]=1.25mM. Stock DNA was used; PCR products were purified on Qiagen columns. Restriction digests were performed at 37°, and products were run on 3% agarose gels.

Results

20 Mutations

EPM2A is composed of 4 exons located within a ~130,000 bp span of chromosome 6q24. Figure 11 shows a refined map of the deletion breakpoints in families LD-L4, LD9 and LD1. Filled symbols indicate patients with LD. Open rectangles on the map are the exons of EPM2A. Genomic structure around exons 1 and 2 is shown to scale. PCR markers 365C1.H65, 266B13, D6S1703A, JRGBF/R, LDXDF/R, 109F4.E.05 and dj28H5T7 were tested. Primer sequences can be obtained by looking up PAC 466P17 at <http://www.sanger.ac.uk>. The positions of the forward primers of these markers on the PAC are at: 58336, 59869, 98214, 108805, 123524, 124039 and 132487 bp respectively. The maximum extent of the deletions are shown on the right. The deletion breakpoint regions for LD-L4 and LD9 are coloured black on the map and are distinct from the deletion breakpoint regions for LD1 are coloured grey. Each of the four deletion breakpoints contains a MIR repeat.

As a first step towards screening exon 2 for mutations, it was amplified by PCR with primers JRGXBF and JRGXBR. In the affected members from three families, LD-L4, LD9 and LD1, no PCR product was observed indicating a possible homozygous deletion in these patients. In order to confirm and characterize the extent of this deletion, PCR was performed with primers covering the rest of the gene (Figure 11). The extent of the deletion in families LD-L4 and LD9 was determined to be ~75,000bp encompassing both exons 1 and 2. A smaller deletion of ~25,000bp was found in family LD1.

Screening Tests for the More Common Mutations

Figure 12 shows restriction endonuclease screening for the two common mutations in exon 4. (A) Restriction map (to scale) of PCR product with primers H1F/PTPR. H, *HaeIII* restriction enzyme sites one of which is destroyed by the C->T mutation; boxed P, *PstI* site created by the G->A mutation. (B) *HaeIII* and *PstI* digestion of the H1F/PTPR PCR product. Lane 1, 1Kb ladder, lane 2: normal non-carrier individual with *HaeIII* digestion, lanes 3 and 4: appearance of an abnormal 199bp band in a carrier with the C->T mutation (lane 3) and a patient with a homozygous mutation (lane 4); lane 5: *PSTI* digestion does not affect normal non-carriers, lane 6: *PstI* digests the PCR product into two smaller fragments in a carrier of the G->A mutation. In patients with a homozygous G->A mutation *PSTI* digestion should result in the disappearance of the 520 bp original band. However, we presently do not have such a patient in our data set.

The most common *EPM2A* mutation to date is a C->T nonsense mutation of the second base pair of exon 4 observed in 9 families (Table 2). Primers H1F and PTPR amplify a 520bp DNA fragment encompassing exon 4 and including several recognition sites for the restriction enzyme *HaeIII*, one of which is destroyed by the C->T mutation. Digestion of this PCR product with *HaeIII* in normal non-carrier individuals results in nine small bands the largest of which is 102bp. Digestion with *HaeIII* in carriers or patients results in the appearance of an abnormal 199bp band (Figure 12A and 12B). Carriers cannot be distinguished from patients who carry this mutation on both chromosomes using this test (Figure 12B).

The second most common mutation is a G → A mutation of bp 115 in exon 4 observed in 4 families (Table 2). This mutation creates a unique *PstI* restriction site in the sequence of the HIF/PTPR PCR product. *PstI* does not digest this 520bp PCR product in normal non-carrier individuals. Carriers will therefore have one normal 520bp band and two variant bands of 195bp and 315bp (Figure 12A and 12B). Patients homozygous for this mutation will only have the abnormal bands.

Finally, several families with deletions of *EPM2A* have been described in Table 2. Two of these families (LD-L4 and LD9) appear to have identical ~75Kb deletions (Figure 11), which are different from the other two (Table 2). Nonetheless these three different deletion mutations all encompass exon 2 (Figure 11, Table 2). Patients homozygous for any of these deletions can be picked up by the absence of PCR amplification using primers JRGXBF/JRGXBR and appropriate controls (Figure 11).

Discussion

LD is most frequently diagnosed in societies with high rates of consanguinity. There also seems to be an excessive reporting from countries surrounding the Mediterranean basin, and many of those families appear not to be consanguineous. This initially suggested that like other PMEs such as Unverricht-Lundborg disease (27) or the Neuronal Ceroid

Lipofuscinoses (28), LD might be caused by a common mutation in most cases. This was shown not to be the case. The large number of different mutations renders their detection for clinical purposes difficult.

The simple DNA-based tests described above can be used to screen for the three more common mutations in the following fashion. Digestion of the HIF/PTPR PCR product with *HaeIII* and *PstI* detects the two more common mutations and will confirm that an individual is a carrier of one or the other mutation. The *PstI* test can further establish whether a patient or fetus is homozygous for the G->A mutation. In order to establish if a patient is homozygous for the mutation detected by the *HaeIII* test, further analyses will be required such as allele specific oligonucleotide hybridization or DNA sequencing.

PCR using JRGXBF/JRGXBR will detect the deletion mutations described in this report, but only in homozygous state. This simple test can therefore serve for prenatal or symptomatic diagnosis, but cannot detect carriers. For carrier testing in these families further work will be required. For example, in three of the deletions (LD-L4, LD9), the polymorphic microsatellite marker *D6S1703* is encompassed in the deletion and can be used to detect carriers by testing for loss of heterozygosity.

The C->T mutation appears to be common in patients of Spanish (or Iberian) origin (Tables 1 and 2). The ~75 Kb deletion was observed in two of two Arabic families in our data set (LD-L4 and LD9). Parenthetically, LD9 is the same Arabic family described in reference 29 in which two affected siblings had discordant biopsy results. While false negative biopsies are usually due to insufficient sampling and/or biopsies done early in the course of the disease, genetic testing should not have these limitations.

Additional *EPM2A* mutations remain to be found as presently we have identified mutations in only 65% of families. Furthermore, we have recently shown that an altogether different gene other than *EPM2A* causes LD in up to 20% of patients including the families from the French Canadian province of Quebec (30). These patients are clinically and pathologically indistinguishable from those with *EPM2A* mutations (30).

Two deletions with different deletion breakpoints are described in this Example. Interestingly, analysis of the sequences of the breakpoint regions revealed the presence of the mammalian-wide interspersed repeat (MIR) (31) in all four breakpoint regions (Figure 11). Duplicated or repetitive sequences flanking deleted genes or exons of a gene have been implicated in the generation of such deletions due to unequal recombinations. A well-studied example of this from the neurological literature is Hereditary Neuropathy with Liability to Pressure Palsies. The putative mechanism in that deletion is complex involving a large *mariner* repeat which codes for a transposase that might facilitate the recombination (32). The role, if any, of the short MIR repeats in the generation of the deletions in our LD patients is now under investigation.

In conclusion, the inventors have identified new *EPM2A* deletion mutations and described DNA-based screening tests for the detection of the more common *EPM2A* mutations. Further mutations in *EPM2A* and in the yet unidentified second gene, *EPM2B*, will improve the role of genetic testing and will provide insights into the function of the gene product laforin and the pathogenesis of LD.

While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

T032020" 2204460

FULL CITATIONS FOR REFERENCES REFERRED TO IN THE SPECIFICATION

1. Delgado-Escueta, A.V., Wilson, W.A., Olsen, R.O., Porter, R.J. Jasper's Basic Mechanisms of the Epilepsies (Lippincott-Raven Publishers, 1998) Chapter 1.
2. Berkovic, S.F., Andermann, F., Carpenter, S., and Wolfe, L.S. 1986. Progressive myoclonus epilepsies: specific causes and diagnosis. New Eng. J. Med. 315, 296-305.
3. Minassian, B.A., Sainz, J. and Delgado-Escueta, A.V. 1996. Genetics of Myoclonic and Myoclonus epilepsies. Clin. Neuroscience 3, 223-235.
4. Van Heycop Ten Ham MW. 1974. Lafora disease, a form of progressive myoclonus epilepsy. Handbook of Clinical Neurology 15:382-422.
- 10 5. Minassian BA, Sainz J, Bohlega S, Sakamoto LM, Delgado-Escueta AV. 1996. Genetic heterogeneity in Lafora's disease. Epilepsia 37 suppl. 5, A126.
6. Lafora, G.R. 1911. Über das vorkommen amyloider körperchen im innern der ganglienzellen; zugleich ein beitrag zum studium der amyloiden substanz im nervensystem. Virchows. Arch. Path. Anat., 205, 295-303.
- 15 7. Harriman, D.G. and Millar, J.H.D. 1955. Progressive familial myoclonic epilepsy in 3 families: its clinical features and pathological basis. Brain 78, 325-349.
8. Schwarz, G.A. and Yanoff, M. 1965. Lafora's disease, distinct clinico-pathologic form of Unverricht's syndrome. Arch Neurol. 12, 172-188.
9. Carpenter S and Karpati G. 1981. Sweat gland duct cells in Lafora disease: 20 Diagnosis by skin biopsy. Neurol. 31:1564-1568.
10. Sakai, M., Austin, J., Witmer, F. and Trueb, L. 1970. Studies in myoclonus epilepsy (Lafora body form). Neurol. 20, 160-176.
11. Carpenter, S., Karpati, G., Andermann, F., Jacob, J.C. and Andermann, E. 1974. Lafora's disease: peroxisomal storage in skeletal muscle. Neurol. 24, 531-538.

T02020-2204460

12. Serratos, J., Delgado-Escueta, A.V., Posada, I., Shih, S., Drury, I., Berciano, J., Zabala, J.A., Antunez, M.C. and Sparkes, R.S. 1995. The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosome 6q. *Hum. Molec. Genet.* 9, 1657-1663.
13. Sainz J., Minassian B. A, Serratos J.M., Gee M.N., Sakamoto L.M., Iranmanesh R., Bohlega S., Baumann R.J., Ryan S., Sparkes R.S., Delgado-Escueta A.V. 1997. Lafora progressive myoclonus epilepsy: narrowing the chromosome 6q24 locus by recombinations and homozygosities. *Am. J. Hum. Genet.* 61(5):1205-1209
14. Denu J. M., Stuckey J. A., Saper M.A., Dixon J. E. 1996. Form and Function in Protein dephosphorylation. *Cell* 87:361-364.
- 10 15. Yuwaniyama J., Denu J.M., Dixon J.E., Saper M.A. 1996. Crystal structure of the dual specificity protein phosphatase VHR. *Science* 272:1328-1331.
16. Tonks N.K., Neel B.G. 1996. From form to function: signaling by protein tyrosine phosphatases. *Cell* 87:365-368.
17. Yokota T. Ishihara T. Yoshida H. Takahashi M. Uchino F. Hamanaka S. 15 1988. Monoclonal antibody against polyglucosan isolated from the myocardium of a patient with Lafora disease. *J. Neuropath. & Exp. Neurol.* 47(5):572-7
18. Thon, V.J., Khalil, M. and Cannon, J.F. 1993. Isolation of human glycogen branching enzyme cDNAs by screening complementation in yeast. *J. Biol. Chem.* 268, 7509-7513
- 20 19. Gurd J.W, Bissoon N. 1997..The N-methyl-D-aspartate receptor subunits NR2A and NR2B bind to the SH2 domains of phospholipase C-gamma. *J. of Neurochem.* Aug;69(2):623-30
20. Llinas R., Moreno H., Sugimori M., Mohammadi M., Schlessinger J. 1997. Differential pre- and postsynaptic modulation of chemical transmission in the squid giant synapse by tyrosine phosphorylation. *Proc. Nat. Acad. Sciences (USA)* 94(5):1990-1994
- 25 21. Laporte J., Hu L.J., Kretz C., Mandel J.L., Kioschis P., Coy J.F., Klauck S.M., Poustka A., Dahl N. 1996. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. *Nat. Genet.* 13(2):175-82

22. Cui X., DeVivo I., Slany R., Miyamoto A., Firestein R., Cleary ML. 1998. Association of SET domain and myotubularin-related proteins modulates growth control. *Nat. Genet.* 18:331-337
23. M. Kozak, 1996, *Mamm. Genome* 7:563.
- 5 24. S. McLaughlin and J.E. Dixon, 1993 *J. Biol. Chem.* , 268:6839.
25. I. Lopes Cendes et al., 1995, *Epilepsia*, 36:S6.
26. J.N. Acharya, P Satishchandra, S.K. Shankar SK. 1995, *Epilepsia*, 36:429.
27. Lafreniere RG, Rochefort DL, Chretien N et al. Unstable insertion in the 5' flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1. *Nat Genet* 1997;15:298-302
- 10 28. Goebel HH. 7th International Congress on Neuronal Ceroid-Lipofuscinoses (NCL-98), 13-16 June 1998, Dallas, USA. *Brain Pathol* 1998;8:809-810
29. Drury I, Blaivas M, Abou-Khalil BW, Beydoun A. Biopsy results in a kindred with Lafora disease. *Arch Neurol* 1993;50:102-105
- 15 30. Minassian BA, Sainz J, Serratosa JM et al. Genetic locus heterogeneity in Lafora's progressive myoclonus epilepsy. *Ann Neurol* 1999;45:262-265
31. Smit AF and Riggs AD. MIRs are classic tRNA-derived SINEs that amplified before the mammalian radiation. *Nucleic Acids Res* 1995;23:98-102
32. Reiter LT, Murakami T, Koeuth T et al. A recombination hotspot responsible for two inherited peripheral neuropathies is located near a *mariner* transposon-like element
- 20 *Nature Genet* 1996;12:288-297

09440-0001
T03020-204460

Table 1. Summary of mutations.

Family	Genetics ¹	Mutation/ (primers used) ²	Predicted effect
LD-L4	consanguineous	homozygous deletion (D6S1703 and 109F4.E0.5)	deletion of the majority of EPM2A
LD100-4	consanguineous	homozygous insertion of A resulting in a frameshift (824F and 824R)	interruption of the tyrosine phosphatase domain
5 I-22	consanguineous	homozygous mutation G → T (JRGXBCF and JRGXBCFR)	glutamic acid → stop
LD-33	consanguineous	homozygous mutation A → T (824F and 824R)	glutamine → leucine
LD-5	consanguineous	homozygous mutation C → T (JRGXBCF and JRGXBCFR)	arginine → cysteine
L6	consanguineous (compound heterozygote)	1. C → T (824R and H1F) 2. G → A (824F and 824R)	1. arginine → stop 2. glycine → serine
LD-16	consanguineous	homozygous mutation C → T (824R and H1F)	arginine → stop
10 LD15	consanguineous	homozygous mutation C → T (824R and H1F)	arginine → stop
LD-48	consanguineous	homozygous mutation C → T (824R and H1F)	arginine → stop
LD13	consanguineous	homozygous mutation C → T (824R and H1F)	arginine → stop

¹ Families L6, LD-16, LD15, LD-48 and LD13 are of common ethnic background.

² The location of the PCR primers and mutations are shown in Figures 3 and 4, respectively.

15 L	Italian	heterozygous mutation	**arginine to stop
M		G to A	
L	Non	**one mutation	**arginine to stop
B	-consanguineous Bolivian ethnicity		codon (one chromosome)

Table 2: Most common *EPM2A* mutations to date

Mutation		n*	Ethnic Origin
1	C->T nonsense	5	Spanish
	mutation of bp 2 of exon 4	2	1Spanish, 1 Italian
2	G->A missense mutation of bp115 of exon 4	1	Spanish
3 (a)	~75kb deletion	2	Arabic
(b)	~25kb deletion	1	Iranian

Total= 17

* n is the number of families with corresponding mutation

TABLE 3

<u>Mutation</u>	<u>Nucleotide Position (Figure 13)</u>	<u>Amino Acid Change (Figure 14)</u>
C → T	721	Arg (241) → stop
insert A	800	Premature stop
G → A	836	Gly (279) → Ser
C → T	163	Glu → Stop
T → G	94	Trp (32) → Gly
A → G	146	Asp (49) → Gly
G → T	412	Glu (138) → stop
A → T	878	Gln (293) → Leu
Delete G	235	Premature stop
G → A	179	Trp (60) → stop
C → T	322	Arg (108) → Cys
C → A	-12	
Deletion (75 kb)	exons 1 and 2	
Deletion (25 kb)	exon 2	

T02020-22044250

We Claim:


1. An isolated nucleic acid molecule containing a sequence encoding a protein tyrosine phosphatase which is associated with Lafora's disease.
2. A nucleic acid according to claim 1 having a sequence as shown in SEQ.ID.NO.:1
5 or Figure 13.
3. An isolated nucleic acid molecule according to claim 1 comprising
 - (a) a nucleic acid sequence as shown in SEQ.ID.NO.:1 or Figure 13, wherein T can also be U;
 - (b) nucleic acid sequences complementary to (a);
 - 10 (c) nucleic acid sequences which are homologous to (a) or (b);
 - (d) a fragment of (a) to (c) that is at least 15 bases, preferably 20 to 30 bases, and which will hybridize to (a) to (d) under stringent hybridization conditions; or
 - (e) a nucleic acid molecule differing from any of the nucleic acids of (a) to (c) in codon sequences due to the degeneracy of the genetic code.
- 15 4. An isolated nucleic acid molecule according to claim 1 having a sequence as shown in Figure 4A.
5. An isolated nucleic acid molecule according to claim 1 having a sequence as shown in Figure 7.
6. An isolated nucleic acid molecule according to claim 1 having a sequence as
20 shown in Figure 9.
7. A method of detecting Lafora's disease comprising detecting a mutation or deletion in a nucleic acid sequence according to any one of claims 1 to 6 in a sample from an animal.
8. A method according to claim 7 comprising detecting a mutation or deletion in a
25 region of the nucleic sequence between markers DS61003 and DS61042.
9. A method according to claim 7 comprising detecting a C to T change in nucleotide number 721 of the sequence shown in SEQ.ID.NO.:1 or Figure 13.

10. A method according to claim 9 wherein the C to T change is detected by a method comprising:
- (a) amplifying the nucleic acid sequences in the sample with primers H1F (5'-GAATGCTCTTTCCACTTTGC-3) and PTPR (5'-GGCTCCTTAGGGAAATCAG-3') in a polymerase chain reaction;
- (b) digesting the amplified sequences with the restriction endonuclease *HaeIII*; and
- (c) determining the size of the digested sequences wherein the presence of a fragment of approximately 199bp indicates the sample is from an animal with Lafora's disease or an animal that is a carrier of Lafora's disease.
11. A method according to claim 7 comprising detecting a G to A mutation of nucleotide number 836 of the sequence shown in SEQ.ID.NO.:1 or Figure 13.
12. A method according to claim 11 wherein the G to A change is detected by a method comprising:
- (a) amplifying the nucleic acid sequences in the sample with primers H1F (5'-GAATGCTCTTTCCACTTTGC-3) and PTPR (5'-GGCTCCTTAGGGAAATCAG-3') in a polymerase chain reaction;
- (b) digesting the amplified sequences with the restriction endonuclease *PstI*; and
- (c) determining the size of the digested sequences wherein the presence of at least one fragment of approximately 520bp indicates that the sample is from an animal that does not have Lafora's disease or an animal that is a carrier of Lafora's disease.
13. A method according to claim 7 comprising detecting a deletion of 75 kb in the sequence of EPM2A shown in SEQ.ID.NO.:1 or Figure 4A.
14. A method according to claim 7 comprising detecting a deletion of 25 kb in the sequence of EPM2A shown in SEQ.ID.NO.:1 or Figure 4A.
15. A method of according to claim 13 or 14 comprising:
- (a) amplifying the nucleic acid sequences in the sample with primers JRGXBF (5'-TCCA TTGTGCTAATGCTATCTC-3') and JRGXBR (5'-TCAGCTTGCTTTGAGGATATTT-3') in a polymerase chain reaction; and
- (b) detecting amplified sequence wherein the absence of an amplified sequence indicates that the sample is from an animal with Lafora's disease.

16. A method according to claim 7 comprising detecting a mutation or deletion as specified in Table 3 in a sample from an animal.
17. An isolated protein containing a tyrosine phosphatase domain which is associated with Lafora's disease.
- 5 18. A protein according to claim 17 having the amino acid sequence as shown in SEQ.ID.NO.:2 or Figure 14.
19. A method for detecting Lafora's disease comprising detecting a deletion or mutation in a protein according to any one of claims 17 or 18.



1/17

FIGURE 1




2/17
FIGURE 2

a




b



D6S409	1 2	1 2
D6S308	1 2	1 1
D6S279	1 2	1 1
D6S1704	1 2	1 1
D6S1003	1 1	1 1
D6S1010	1 1	1 1
D6S1049	1 1	1 1
D6S1703	1 1	1 1
D6S1042	1 2	1 2
D6S1649	1 2	1 2
D6S978	1 2	1 2
D6S311	1 2	1 2
D6S1637	1 2	1 2

3/17

FIGURE 3



4/17

FIGURE 4


a

```

1 GGTGGAGCTGGCGGCCGAGGAGGCGGCGCAGGACGGGCGGAGCGCGGCCGCTGGACAC
1 V E L A A E E A A Q D G A E P G R V D T
61 GTTCTGGTACAACTTCCTGAAGCGGAGCGGAGGAGAGCTCTCTGGGAAGCAATGG
21 F W Y K F L K R E P G G E L S W E G N G
121 ACCTCATCATGACCGTTGCTGTACTTACAATGAAAACTTGGTGGATGCTGTGTATTG
41 F H H E R C C T A N E N N L V D G V C
C (LD5) T (polymorphism)
181 TCTCCCAATAGGACACTGGATTGAGGCCACTGGACACCAATGAAATGAAGCACACAAC
61 L P I G H W I E A T G H T N E M K H T T
(I-22) *
241 AGACTTCTATTTTAATATTGCGGCCACCAAGCCATGCATTATTCAGAATTCTACCAA
81 D F Y F N I A G H Q A M H Y S R I L P N
301 TATCTGGCTGGGTAGCTGCCCTCGACAGGTGGAACATGTTACCATCAAATGAAGCATGA
101 I W L G S C P R Q V E H V T I K L K H E
361 ATTGGGGATTACAGCTGTCTGAATTTCCAGACTGAATGGGATATTGTTTCAGAAATTCCTC
121 L G I T A V M N P Q T E W D I V Q N S S
421 ATGCTGTAAACCGCTACCCAGAGCCCATGACTCCAGACACTATGATTAACTATCTAGGGA
141 C C N R Y P E P M T P D T M I K L S R E
481 AGAAGGCTTGGCTTACATCTGGATGCCAACACAGATATGAGCAGCGCAGGCGGAGTACA
161 E G L A Y I W M P T P D M S T A G R V Q
(6 families) *
541 GATGCTGCCCCAGGCGGTGTGCTGCTGCAATGCGCTGCTGGAGAAGGGACACATCGTGT
181 M L P Q A V C L L H A L L E K G H I V Y
A insertion (LD100)
601 CGTGCACCTGCAACGCTGGGGTGGGCGGCTCCACCGCGGCTGTCTGCGGCTGGCTCCAGTA
201 V H C N A G V G R S T A A V C G W L Q Y
S (L6)
661 TGTGATGGGCTGGAATCTGAGGAAGGTGCAGTATTTCTCATGGCCAAGAGGCGGCTGT
221 V M G W N L R K V Q Y F L M A K R P A V
L (LD33)
721 CTACATTGACGAAGAGGCGCTTGGCCCGGGCACAAGAAGATTTTTCAGAAATTTGGGAA
241 Y I D E A L A R A Q E D F F Q K F G K
781 GGTTCTGTTCTCTGTGTAGCCTGTAGCgtggtcagcctgctctgtccccctcctgattt
261 V R S S V C S L *
841 ccctaaggagcctgggatgatgttgggtcaaatgacctagaacaaggattctacctgaac
901 tgaaggactgtgtgacctcccccaagccaacctttacctgggatgactttcgattat
961 gctttgggtttggggctgtatcttttgaataactctacaagaaagctgtggctcaacacatg
1021 agaagaagcaggaagcagtttaggtgtacatcagacagaagggttaagtgcgtgcagttcct
1081 gctgcctgcaggcagacgagggcctttgctttacagcactgtatgtttgcagatggatc
1141 cgtgacagcactttcctgtgtcactgaaactcttggcctatgtagaggaaagatattggag
1201 ttatgtggattttcatcactagtatgtgtgcgtgagctggctcagttgccaaggaggaaa
1261 taaggttagaagcctgaacctgttacaagaagagcctcactatgggtcaaaaagtgtatggc
1321 tttcaggactgttttttctcctgcctcacagttgttaagctgttcccaaggcatcac
1381 ttccttctctaccacaacacctgtgttaacaactaaagtataatctctcatttgggtg
1441 gtgggtttttctcaaaattaccaaaacaaagcaaaaaataacctgtttttttagttgag
1501 atgtcaaggaagttaaatgaggccttaagtgcagataggtagctgttccaaggtctcatga
1561 ccagtcagggaagctggagtttaataatctatatttattgactcagcactgtttctat
1621 cacaactgtttttccagcatcatgtagtgcatttagttttgtctttctcagggtatagt
1681 caatatgcctgcaggagtttctatagcgagacatagaatagtattctgacagttggcaa
1741 agaactcaggaaatttagttgtattttgtgcaagcatttaaaaacatgatgggtgttt
1801 taagaccagagtggaattctatgagaggaactatactacaaaagagcccaaatgaccaa
1861 atccatggataattgtctcagcagccttgccatcctggctcagctctcaatttagtataa
1921 tatgcagttcctgtgcctccagactatgcagctcatcacctcaggtttctacaggaaatac
1981 agagatgaacaactttgccttcaaaaaatgtgctgcctagaaaacagacctgcatttcaa
2041 cccaaactgtaaatgcaggtatttgaccatgaatgatagctagaatagaagaaagagaagt
2101 gtttttttaattgagagcctctatgtgcaaggtgatataaatcatatccagtttaactc
2161 tcacaatatccaatgaagaaggtctcattatctccatgataaagatggggaaactaaggt
2221 cagaagggttaactcaactgtctattgtcacatgatgaataaatagatgaagtgaagatc
2281 aaagctgggtttgattcaaaagccttactttcttaattaaactatgatgcgtatttattt
2341 ttctgcaccttctcttctccacaaacacatattgatagatgcaagagactcttatttat
2401 aaggcgtgggggacaagaaggatacaaggttaagtttcagtggagctcagaggacggggag
2461 atagaactgtggcacttaggggagatgacatttgcctttgggcagagggagctagccagg
2521 cacattttccactataattttacaaagttaaaattataagctagcattaaagtaagtgaa
2581 tccagctcccttgcataaaataactagaggttaataattgtgattcaggttaactcatttac
2641 agtcataatgtgtgtgaaaaatttaactcttaaaaaattaaaatttttaactatgtgggtct
2701 gtgaatttctttaaattgttaagaaatccagctctcataatttccatgatataaagatctt
2761 tttcaggtggattttacctttgttctttgtctgtatagacaaaatcagtttaggact
2821 attaaagaatgttttggaaatactgtcttttctcctcaatgaatgggatgtctaattgtat
2881 ttcaaaatcaccccaaaatttttgcagatgaagcatttaaaagaaaaa

```

b




c

LD1	VHCNAGVGRST
MTM1	VHCSGWDRTA
PTEN	IHKAKGKRTG
PTP1B	VHCSAGIGRSG
dPTP61F	VHCSAGIGRSG
virus	VHCOAGISRSA


5/17

FIGURE 5



6/17

FIGURE 6



7/17

FIGURE 7 (P1)

LDA

LDA.seq Length: 2940 July 16, 1998 10:34 Type: N Check: 4100 ..

1 GGTGGAGCTG GCGGCCGAGG AGGCGGCGCA GGACGGGGCG GAGCCGGGCC
51 GCGTGGACAC GTTCTGGTAC AAGTTCCTGA AGCGGGAGCC GGGAGGAGAG
101 CTCTCCTGGG AAGGCAATGG ACCTCATCAT GACCGTTGCT GTACTTACAA
151 TGAAAACAAC TTGGTGGATG GTGTGTATTG TCTCCCAATA GGACACTGGA
201 TTGAGGCCAC TGGACACACC AATGAAATGA AGCACACAAC AGACTTCTAT
251 TTTAATATTG CAGGCCACCA AGCCATGCAT TATTCAAGAA TTCTACCAAA
301 TATCTGGCTG GGTAGCTGCC CTCGACAGGT GGAACATGTT ACCATCAAAC
351 TGAAGCATGA ATTGGGGATT ACAGCTGTCA TGAATTTCCA GACTGAATGG
401 GATATTGTTT AGAATTCCTC ATGCTGTAAC CGTACCCAG AGCCCATGAC
451 TCCAGACACT ATGATTAAAC TATCTAGGGA AGAAGGCTTG GCCTACATCT
501 GGATGCCAAC ACCAGATATG AGCACCGCAG GCCGAGTACA GATGCTGCCC
551 CAGGCGGTGT GCCTGCTGCA TGCCTGCTG GAGAAGGGAC ACATCGTGTA
601 CGTGCACTGC AACGCTGGGG TGGGCCGCTC CACCGCGGCT GTCTGCGGCT
651 GGCTCCAGTA TGTGATGGGC TGAATCTGA GGAAGGTGCA GTATTTCTC
701 ATGGCCAAGA GGCCGGCTGT CTACATTGAC GAAGAGGCCT TGGCCCGGGC
751 ACAAGAAGAT TTTTCCAGA AATTTGGGAA GGTTCTGTTCT TCTGTGTGTA
801 GCCTGTAGCT GGTCAGCCTG CTTCTGCCCC CTCCTGATTT CCCTAAGGAG
851 CCTGGGATGA TGTGGTCAA ATGACCTAGA AACAAGGATT CTACCTGAAC
901 TGAAAGGACT GTGTGACCTC CCCAAGCCAA CCACTTTCAC CTGGGATGAC
951 TTTCGATTAT GCTTTGGTTT GGGGCTGTAT TTTTGAAATA CTCTACAAGA
1001 AAGCTGTGGC TCAACACATG AGAAGAAGCA CGAAGCAGTT AGGCTGTACA
1051 TCAGACAGAA GGGTAATGCG TGCAGTTCCT GCTGCCTGCA GGCAGACGAG
1101 GCCTTTGCTT TACAGCACTG TATGTGTTGC ACGATGGATC CGTGACAGCA
1151 CTTTCCTGTT GCACTGAAAC TCTTGGCCAT GTAGAGGAAA AGATATGGAG
1201 TTATGTGGAT TTCATCACTA GTATGTGTGC CGTGAGCTGG TCAGTTGCCA
1251 AAGGAGGAAA TAAGGTTAGA AGCCTGAACC GTTACAAAAG AAGAGCTCAC

FIGURE 7 (P2)

1301 TATGGTCAAA AAGTGATGGC TTTCAGGACT TGTTTTTTAT CCTGCCTCAC
1351 AGTTGTAAAA GTCTGTTCCA AGGCATCACC TTCCTTCTCT ACCCAACAAC
1401 CCTGTGTAAC AACTAAAGTA GAATTATCTC TCATTGTGTG GTGGTTTTTC
1451 CTCAAAATTA CCAAACAAAG CAAAAAATAC CCTTGTTTTT TATAGTTGAG
1501 ATGTCAAGGA AGTTAAATTG AGGCTTAATG AGCATAGGTA GCTTGTCCAA
1551 GGTCTCATGA CCAGTCAAGG GCAAGCTGGA GTTAATAATC TATATTTATT
1601 TGA CTCAGCA CTGTTTTTCAT CACAACCTGT TTTCCAGCA TCATGTAGTG
1651 CATTTAGTTT TGTCTTTCTC AGGGTATAGT CAATATGCCT GCAGGAGTTT
1701 CTATAGCGAG ACATAGAATA GTATTCTGAT CAGTTGCCAA AGAATCTAGG
1751 AAATTAGTTG TATTTTGTGC AAGCTAATTT AAAAACATGA TGGGCTGTTT
1801 TAAGACCAGA GTGGAAATTC ATGAGAGGAA CTATACTACC AAAAGAGCCC
1851 AAATGACCAA ATCCATGGAT AATTGCTTCA CAGCCTTGGC CATCCTGGCT
1901 CAGCTCTCAA TTTAGTATAA TATGCAGTTC CTGTGCCTCC AGACTATGCA
1951 GCTCATCACC CTAGGTTCTA CAGGAAATAC AGAGATGAAC AACTTTGCCT
2001 TCAAAAAATG TGCTGCCTAG AAAACAGACC TGCATTTCAA CCCAACTGTA
2051 ATGCAGGATT TGGACCATGA ATGATATGCT AGAATAGAAG AAAGAGAAGT
2101 GTTTTTTTAA TTGAGAGCCT CTATGTGCAA GGTGATATAT AATCATATCC
2151 AGTTTAATCT TCACAATATC CAATGAAGAA GGTCTCATT TCTCCATGAT
2201 AAAGATGGGG AAATAAGGT CAGAAGGGT AACTCAACTG TCTATTGTCA
2251 CATGATGAAT AAATAGATGA AGTGAGATAC AAAGCTGGGT TTGATTCAAA
2301 GCCCTTACTT TCCTAATTAA ACTATGATGC GTATTTATTT TTCTGCACCT
2351 TCCTTTCTTC CACAAACACA TATTGATAGA TGCAAGAGAC TCTTATTTAT
2401 AAGGCGTGGG GGACAAGAAG GATACAAGGT AAGTTTCAGT GGAGCTCAGA
2451 GGACGGGGAG ATAGAACTGT GGCACCTAGG GGAGATGACA TTTGCTTTGG
2501 GCAGAGGCAG CTAGCCAGGA CACATTTCCA CTATAATTTT ACAAAGTTAA
2551 ATTTATAAGC TAGCATTAAAG TAAAGTGAAG TCCAGCTCCC TTGCTAAAAA
2601 TAACTAGAGG TAATAATTGG TATTCAGGTA ACTCATTTAC AGTCATAATG
2651 TGTTGTGAAA ATTTAATCTT AAAAATTAAA TTTTAAACT ATGTGGGTCT

9/17

FIGURE 7 (P3)

2701 GTGAATTTCT TTAATGTCTA AGAAATCCAG CTCATAATT TCCATGATAC
2751 AAAGATCTTT TTTCAGGTGG ATTTTACCT TTGTTCTTT TGCTCTGATA
2801 GACAAAATCA GTTTAGGACT ATTAAAGAAT GTTTTGAAT AAAGTGTCTT
2851 TTTCCTCAAT GAATGGGATG TCTAATGTAT TTCAAAAATCA CCCAAAACCT
2901 TTGGCAAATA AAAGCATTTA AAAAGAAAAA AAAAAAAAAA

10/17

FIGURE 8

LDA.pep Length: 268 July 16, 1998 10:33 Type: P Check: 9839 ..

1 VELAAEEAAQ DGAEPGRVDT FWYKFLKREP GGELSWEGNG PHHDCCTYN
51 ENNLVDGVYC LPIGHWIEAT GHTNEMKHTT DFYFNIAGHQ AMHYSRILPN
101 IWLGSCPRQV EHVTIKLKHE LGITAVMNFQ TEWDIVQNSS CCNRYPEPMT
151 PDTMIKLSRE EGLAYIWMPT PDMSTAGRVQ MLPQAVCLLH ALLEKGHIVY
201 VHCNAGVGRS TAAVCGWLQY VMGWNLRKVQ YFLMAKRPAV YIDEEALARA
251 QEDFFQKFGK VRSSVCSL

0944072.0001

11/17

FIGURE 9

LDB.seq Length: 915 July 16, 1998 10:34 Type: N Check: 2239 ..

1 CCAAGAATCG GCACGAGGAT TATTCAAGAA TTCTACCAA TATCTGGCTG
51 GGTAGCTGCC CTCGACAGGT GGAACATGTT ACCATCAAAC TGAAGCATGA
101 ATTGGGGATT ACAGCTGTCA TGAATTTCCA GACTGAATGG GATATTGTTC
151 AGAATTCCTC ATGCTGTAAC CGCTACCCAG AGCCCATGAC TCCAGACACT
201 ATGATTAAAC TATCTAGGGA AGAAGGCTTG GCCTACATCT GGATGCCAAC
251 ACCAGATATG AGCACCGCAG GCCGAGTACA GATGCTGCCC CAGGCGGTGT
301 GCCTGCTGCA TGCCTGCTG GAGAAGGGAC ACATCGTGTA CGTGCACTGC
351 AACGCTGGGG TGGGCCGCTC CACCGCGGCT GTCTGCGGCT GGCTCCAGTA
401 TGTGATGGGC TGAATCTGA GGAAGGTGCA GTATTTCTC ATGGCCAAGA
451 GGCCGGCTGT CTACATTGAC GAAGAGGCAG CTAGCCAGGA CACATTTCCA
501 CTATAATTTT ACAAAGTTAA ATTTATAAGC TAGCATTAAG TAAAGTGAAG
551 TCCAGCTCCC TTGCTAAAAA TAACTAGAGG TAATAATTGG TATTCAGGTA
601 ACTCATTTAC AGTCATAATG TGTGTGAAA ATTTAATCTT AAAAATTAAA
651 TTTTAAACT ATGTGGGTCT GTGAATTTCT TTAATGTCTA AGAAATCCAG
701 CTTCATAATT TCCATGATAC AAAGATCTTT TTTCAGGTGG ATTTTACCT
751 TTGTTCTTT TGCTCTGATA GACAAAATCA GTTAGGACT ATTAAGAAT
801 GTTTTGGAAT AACTGTCTT TTTCTCAAT GAATGGGATG TCTAATGTAT
851 TTCAAAATCA CCCAAACTT TTGGCAAATA AAAGCATTTA AAAAGAAAAA
901 AAAAAAAAAA AAAAA


12/17

FIGURE 10

LDB.pep Length: 167 July 16, 1998 10:34 Type: P Check: 3130 ..


1 KNRHEDYSRI LPNIWLGSCP RQVEHVTIKL KHELGITAVM NFQTEWDIVQ
51 NSSCCNRYPE PMTPDTMIKL SREEGLAYIW MPTPDMSTAG RVQMLPQAVC
101 LLHALLEKGH IVYVHCNAGV GRSTAAVCGW LQYVMGWNLR KVQYFLMAKR
151 PAVYIDEEAA SQDTFPL

13/17
FIGURE 11




14/17
FIGURE 12

A.



B.



15/17

FIGURE 13 (P1)

1 ATGCGCTTCC GCTTTGGGGT GGTGGTGCCA CCCGCCGTGG CCGGCGCCCCG
51 GCCGGAGCTG CTGGTGGTGG GGTGCGGGCC CGAGCTGGGG CGTTGGGAGC
101 CGCGCGGTGC CGTCCGCCTG AGGCCGGCCG GCACCGCGGC GGGCGACGGG
151 GCCCTGGCGC TGCAGGAGCC GGGCCTGTGG CTCGGGGAGG TGGAGCTGGC
201 GGCCGAGGAG GCGGCGCAGG ACGGGGCGGA GCCGGGCCGC GTGGACACGT
251 TCTGGTACAA GTTCTGAAG CGGGAGCCGG GAGGAGAGCT CTCCTGGGAA
301 GGCAATGGAC CTCATCATGA CCGTTGCTGT ACTTACAATG AAAACAACCT
351 GGTGGATGGT GTGTATTGTC TCCCAATAGG AACTGGATT GAGGCCACTG
401 GGCACACCAA TGAAATGAAG CACACAACAG ACTTCTATTT TAATATTGCA
451 GGCCACCAAG CCATGCATTA TTCAAGAATT CTACCAAATA TCTGGCTGGG
501 TAGCTGCCCT CGTCAGGTGG AACATGTTAC CATCAAACCTG AAGCATGAAT
551 TGGGGATTAC AGCTGTAATG AATTTCCAGA CTGAATGGGA TATTGTACAG
601 AATTCCTCAG GCTGTAACCG CTACCCAGAG CCCATGACTC CAGACACTAT
651 GATTAAACTA TATAGGGAAG AAGGCTTGGC CTACATCTGG ATGCCAACAC
701 CAGATATGAG CACCGAAGGC CGAGTACAGA TGCTGCCCCA GGCGGTGTGC
751 CTGCTGCATG CGCTGCTGGA GAAGGGACAC ATCGTGTACG TGCCTGCAA
801 CGCTGGGGTG GGCCGCTCCA CCGCGGCTGT CTGCGGCTGG CTCCAGTATG
851 TGATGGGCTG GAATCTGAGG AAGGTGCAGT ATTTCTCAT GGCCAAGAGG
901 CCGGCTGTCT ACATTGACGA AGAGGCCTTG GCCCGGGCAC AAGAAGATTT
951 TTTCCAGAAA TTTGGGAAGG TTCGTTCTTC TGTGTGTAGC CTGTAGCTGG
1001 TCAGCCTGCT TCTGCCCCCT CCTGATTTC CTAAGGAGCC TGGGATGATG
1051 TTGGTCAAAT GACCTAGAAA CAAGGATTCT ACCTGAACTG AAAGGACTGT
1101 GTGACCTCCC CAAGCCAACC ACTTTCACCT GGGATGACTT TCGATTATGC
1151 TTTGGTTTGG GGCTGTATTT TTGAAATACT CTACAAGAAA GCTGTGGCTC
1201 AACACATGAG AAGAAGCACG AAGCAGTTAG GCTGTACATC AGACAGAAGG
1251 GTAATGCGTG CAGTTCCTGC TGCCTGCAGG CAGACGAGGC CTTTGCTTTA
1301 CAGCACTGTA TGTGTTGCAC GATGGATCCG TGACAGCACT TTCCTGTTGC
1351 ACTGAAACTC TTGGCCATGT AGAGGAAAAG ATATGGAGTT ATGTGGATTT
1401 CATCACTAGT ATGTGTGCCG TGAGCTGGTC AGTTGCCAAA GGAGGAAATA
1451 AGGTTAGAAG CCTGAACCGT TACAAAAGAA GAGCTCACTA TGGTCAAAAA
1501 GTGATGGCTT TCAGGACTTG TTTTTTATCC TGCCTCACAG TTGTTAAAGT
1551 CTGTTCCAAG GCATCACCTT CCTTCTCTAC CCAACAACCC TGTGTAACAA
1601 CTAAAGTAGA ATTATCTCTC ATTTGTTGGT GGTTTTTCCT CAAAATTACC
1651 AAACAAAGCA AAAAATACCC TTGTTTTTTA TAGTTGAGAT GTCAAGGAAG
1701 TTAAATTGAG GCTTAATGAG CATAGGTAGC TTGTCCAAGG TCTCATGACC
1751 AGTCAAGGGC AAGCTGGAGT TAATAATCTA TATTTATTTG ACTCAGCACT
1801 GTTTTCATCA CAACTTGTTT TCCCAGCATC ATGTAGTGCA TTTAGTTTTG

16/17

FIGURE 13 (P2)

1851	TCTTTCTCAG	GGTATAGTCA	ATATGCCTGC	AGGAGTTTCT	ATAGCGAGAC
1901	ATAGAATAGT	ATTCTGATCA	GTTGCCAAAG	AATCTAGGAA	ATTAGTTGTA
1951	TTTTGTGCAA	GCTAATTTAA	AAACATGATG	GGCTGTTTTA	AGACCAGAGT
2001	GGAAATTCAT	GAGAGGAACT	ATACTACCAA	AAGAGCCCAA	ATGACCAAAT
2051	CCATGGATAA	TTGCTTCACA	GCCTTGGCCA	TCCTGGCTCA	GCTCTCAATT
2101	TAGTATAATA	TGCAGTTCCT	GTGCCTCCAG	ACTATGCAGC	TCATCACCCCT
2151	AGGTTCTACA	GGAAATACAG	AGATGAACAA	CTTTGCCTTC	AAAAAATGTG
2201	CTGCCTAGAA	AACAGACCTG	CATTTCAACC	CAACTGTAAT	GCAGGATTTG
2251	GACCATGAAT	GATATGCTAG	AATAGAAGAA	AGAGAAGTGT	TTTTTTAATT
2301	GAGAGCCTCT	ATGTGCAAGG	TGATATATAA	TCATATCCAG	TTTAATCTTC
2351	ACAATATCCA	ATGAAGAAGG	TCTCATTATC	TCCATGATAA	AGATGGGGAA
2401	ACTAAGGTCA	GAAGGGTTAA	CTCAACTGTC	TATTGTCACA	TGATGAATAA
2451	ATAGATGAAG	TGAGATACAA	AGCTGGGTTT	GATTCAAAGC	CCTTACTTTC
2501	CTAATTAAAC	TATGATGCGT	ATTTATTTTT	CTGCACCTTC	CTTTCTTCCA
2551	CAAACACATA	TTGATAGATG	CAAGAGACTC	TTATTTATAA	GGCGTGGGGG
2601	ACAAGAAGGA	TACAAGGTAA	GTTTCAGTGG	AGCTCAGAGG	ACGGGGAGAT
2651	AGAACTGTGG	CACTTAGGGG	AGATGACATT	TGCTTTGGGC	AGAGGCAGCT
2701	AGCCAGGACA	CATTTCCACT	ATAATTTTAC	AAAGTTAAAT	TTATAAGCTA
2751	GCATTAAGTA	AAGTGAAGTC	CAGCTCCCTT	GCTAAAAATA	ACTAGAGGTA
2801	ATAATTGGTA	TTCAGGTAAC	TCATTTACAG	TCATAATGTG	TTGTGAAAAT
2851	TTAATCTTAA	AAATTAAATT	TTTAAACTAT	GTGGGTCTGT	GAATTTCTTT
2901	AATGTCTAAG	AAATCCAGCT	TCATAATTTT	CATGATACAA	AGATCTTTTT
2951	TCAGGTGGAT	TTTTACCTTT	GTTTCCTTTT	CTCTGATAGA	CAAAATCAGT
3001	TTAGGACTAT	TAAAGAATGT	TTTGGAATAA	ACTGTCTTTT	TCCTCAATGA
3051	ATGGGATGTC	TAATGTATTT	CAAAATCACC	CAAAACTTTT	GGCAAATAAA
3101	AGCATTTAAA	AAGAAAAAAA	AAAAAAA		

17/17

FIGURE 14

MRFRFGVVVPPAVAGARPELLVVGSRPELGRWEPRGAVRLRPAGTAAGDG
ALALQEPGLWLGEVELAAEEAAQDGAEPGRVDTFWYKFLKREPGGELSWE
GNGPHHDCCTYNENNLVDGVYCLPIGHWIEATGHTNEMKHTTDFYFNIA
GHQAMHYSRILPNIWLGSCPRQVEHVTIKCLKHELGITAVMNFQTEWDIVQ
NSSGCNRYPEPMTPTDTMIKLYREEGLAYIWMPTPDMSTEGRVQMLPQAVC
LLHALLEKGHIVYVHCNAGVGRSTAAVCGWLQYVMGWNLRKVQYFLMAKR
PAVYIDEEALARAQEDFFQKFGKVRSSVCSL

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

LAFORA'S DISEASE GENE

(Attorney Docket No. 086671/0113)

the specification of which (check one)

 is attached hereto.

 X was filed on July 20, 1999 as United States Application Number or PCT International Application Number PCT/CA99/00646 and was amended on (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?
			Yes	
			yes	

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date
60/093,495	July 20, 1998
60/130,269	April 21, 1999

I HEREBY CLAIM the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number

I HEREBY APPOINT the following registered attorneys and agents of the law firm of FOLEY & LARDNER:

STEPHEN A. BENT	Reg. No. 29,768
DAVID A. BLUMENTHAL	Reg. No. 26,257
BETH A. BURROUS	Reg. No. 35,087
ALAN I. CANTOR	Reg. No. 28,163
WILLIAM T. ELLIS	Reg. No. 26,874
JOHN J. FELDHAUS	Reg. No. 28,822
PATRICIA D. GRANADOS	Reg. No. 33,683
JOHN P. ISACSON	Reg. No. 33,715

MICHAEL D. KAMINSKI	Reg. No. 32,904
LYLE K. KIMMS	Reg. No. 34,079
KENNETH E. KROSIN	Reg. No. 25,735
JOHNNY A. KUMAR	Reg. No. 34,649
JACK LAHR	Reg. No. 19,621
GLENN LAW	Reg. No. 34,371
PETER G. MACK	Reg. No. 26,001
BRIAN J. MC NAMARA	Reg. No. 32,789
SYBIL MELOY	Reg. No. 22,749
RICHARD C. PEET	Reg. No. 35,792
GEORGE E. QUILLIN	Reg. No. 32,792
BERNHARD D. SAXE	Reg. No. 28,665
CHARLES F. SCHILL	Reg. No. 27,590
RICHARD L. SCHWAAB	Reg. No. 25,479
HAROLD C. WEGNER	Reg. No. 25,258

to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith.

I request that all correspondence be directed to:

Bernhard D. Saxe
FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109

Telephone: (202) 672-5427
 Facsimile: (202) 672-5399

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of first inventor	<u>Stephen W. SCHERER</u>
Residence	<u>Toronto, Ontario, Canada</u>
Citizenship	<u>Canada</u>
Post Office Address	<u>60 Mayfield Avenue, Toronto, Ontario, Canada M6S 1K5</u>
Inventor's signature	<u><i>S. W. Scherer</i></u>
Date	<u>March 19th 2001</u>

2 - 8 Name of second inventor

Berge A. MINASSIAN

Residence

Toronto, Ontario, Canada CA AX

Citizenship

Canada

Post Office Address

18 Vanderhoff Avenue, Toronto, Ontario, Canada M4G
2H1

Inventor's signature

Date

X [Signature] SWS
X March 20, 01

Name of third inventor

Antonio Delgado-Escueta

Residence

Malibu, CA

Citizenship

USA

Post Office Address

28342 Rey De Copas Lane, Malibu, CA 90265

Inventor's signature

Date

X
X

Name of fourth inventor

Guy Rouleu

Residence

Montreal, Quebec, Canada

Citizenship

Canada

Post Office Address

4850 Cote St., Luc Road, Montreal, Quebec, Canada
H3W 2H2

Inventor's signature

Date

X
X

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

LAFORA'S DISEASE GENE

(Attorney Docket No. 086671/0113)

the specification of which (check one)

 is attached hereto.

 X was filed on July 20, 1999 as United States Application Number or PCT International Application Number PCT/CA99/00646 and was amended on (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?
			Yes	
			yes	

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date
60/093,495	July 20, 1998
60/130,269	April 21, 1999

I HEREBY CLAIM the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number

I HEREBY APPOINT the following registered attorneys and agents of the law firm of FOLEY & LARDNER:

STEPHEN A. BENT	Reg. No. 29,768
DAVID A. BLUMENTHAL	Reg. No. 26,257
BETH A. BURROUS	Reg. No. 35,087
ALAN I. CANTOR	Reg. No. 28,163
WILLIAM T. ELLIS	Reg. No. 26,874
JOHN J. FELDHAUS	Reg. No. 28,822
PATRICIA D. GRANADOS	Reg. No. 33,683
JOHN P. ISACSON	Reg. No. 33,715

MICHAEL D. KAMINSKI	Reg. No. 32,904
LYLE K. KIMMS	Reg. No. 34,079
KENNETH E. KROSIN	Reg. No. 25,735
JOHNNY A. KUMAR	Reg. No. 34,649
JACK LAHR	Reg. No. 19,621
GLENN LAW	Reg. No. 34,371
PETER G. MACK	Reg. No. 26,001
BRIAN J. MC NAMARA	Reg. No. 32,789
SYBIL MELOY	Reg. No. 22,749
RICHARD C. PEET	Reg. No. 35,792
GEORGE E. QUILLIN	Reg. No. 32,792
BERNHARD D. SAXE	Reg. No. 28,665
CHARLES F. SCHILL	Reg. No. 27,590
RICHARD L. SCHWAAB	Reg. No. 25,479
HAROLD C. WEGNER	Reg. No. 25,258

to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith.



I request that all correspondence be directed to:

Bernhard D. Saxe
 FOLEY & LARDNER
 Washington Harbour
 3000 K Street, N.W., Suite 500
 Washington, D.C. 20007-5109

Telephone: (202) 672-5427
 Facsimile: (202) 672-5399

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of first inventor	Stephen W. SCHERER
Residence	Toronto, Ontario, Canada
Citizenship	Canada
Post Office Address	60 Mayfield Avenue, Toronto, Ontario, Canada M6S 1K5
Inventor's signature	
Date	

002.438741.1

Name of second inventor Berge A. MINASSIAN
 Residence Toronto, Ontario, Canada
 Citizenship Canada
 Post Office Address 18 Vanderhoff Avenue, Toronto, Ontario, Canada M4G 2H1
 Inventor's signature *[Signature]*
 Date *[Signature]*

Name of third inventor Antonio Delgado-Escueta
 Residence Malibu, CA
 Citizenship USA
 Post Office Address 28342 Rey De Copas Lane, Malibu, CA 90265
 Inventor's signature *[Signature]*
 Date 3/22/01

Name of fourth inventor Guy Rouleu
 Residence Montreal, Quebec, Canada
 Citizenship Canada
 Post Office Address 4850 Cote St., Luc Road, Montreal, Quebec, Canada H3W 2H2
 Inventor's signature *[Signature]*
 Date *[Signature]*

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

LAFORA'S DISEASE GENE

(Attorney Docket No. 086671/0113)

the specification of which (check one)

 is attached hereto.

 X was filed on July 20, 1999 as United States Application Number or PCT International Application Number PCT/CA99/00646 and was amended on (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?
			Yes	
			yes	

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date
60/093,495	July 20, 1998
60/130,269	April 21, 1999

I HEREBY CLAIM the benefit under Title 35, United States Code, §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number

I HEREBY APPOINT the following registered attorneys and agents of the law firm of FOLEY & LARDNER:

STEPHEN A. BENT	Reg. No. 29,768
DAVID A. BLUMENTHAL	Reg. No. 26,257
BETH A. BURROUS	Reg. No. 35,087
ALAN I. CANTOR	Reg. No. 28,163
WILLIAM T. ELLIS	Reg. No. 26,874
JOHN J. FELDHAUS	Reg. No. 28,822
PATRICIA D. GRANADOS	Reg. No. 33,683
JOHN P. ISACSON	Reg. No. 33,715

MICHAEL D. KAMINSKI	Reg. No. 32,904
LYLE K. KIMMS	Reg. No. 34,079
KENNETH E. KROSIN	Reg. No. 25,735
JOHNNY A. KUMAR	Reg. No. 34,649
JACK LAHR	Reg. No. 19,621
GLENN LAW	Reg. No. 34,371
PETER G. MACK	Reg. No. 26,001
BRIAN J. MC NAMARA	Reg. No. 32,789
SYBIL MELOY	Reg. No. 22,749
RICHARD C. PEET	Reg. No. 35,792
GEORGE E. QUILLIN	Reg. No. 32,792
BERNHARD D. SAXE	Reg. No. 28,665
CHARLES F. SCHILL	Reg. No. 27,590
RICHARD L. SCHWAAB	Reg. No. 25,479
HAROLD C. WEGNER	Reg. No. 25,258

to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith.



I request that all correspondence be directed to:

Bernhard D. Saxe
 FOLEY & LARDNER
 Washington Harbour
 3000 K Street, N.W., Suite 500
 Washington, D.C. 20007-5109

Telephone: (202) 672-5427
 Facsimile: (202) 672-5399

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of first inventor	Stephen W. SCHERER
Residence	Toronto, Ontario, Canada
Citizenship	Canada
Post Office Address	60 Mayfield Avenue, Toronto, Ontario, Canada M6S 1K5
Inventor's signature	
Date	

Name of second inventor Berge A. MINASSIAN
 Residence Toronto, Ontario, Canada
 Citizenship Canada
 Post Office Address 18 Vanderhoff Avenue, Toronto, Ontario, Canada M4G 2H1
 Inventor's signature X
 Date X

Name of third inventor Antonio Delgado-Escueta
 Residence Malibu, CA
 Citizenship USA
 Post Office Address 28342 Rey De Copas Lane, Malibu, CA 90265
 Inventor's signature X
 Date X

4 - 00 , Name of fourth inventor Guy Rouleu
 Residence Montreal, Quebec, Canada CAX
 Citizenship Canada
 Post Office Address 4850 Cote St., Luc Road, Montreal, Quebec, Canada H3W 2H2
 Inventor's signature X
 Date March 30 2001